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ABSTRACT 
  Diabetes mellitus is a group of metabolic disorders characterized by 
hyperglycemia. The pathogenesis of these diseases involves β-cell dysfunction and death. 
The primary function of β-cells is to tightly regulate the secretion, production, and 
storage of insulin in response to blood glucose levels. In order to manage insulin 
biosynthesis, β-cells have an elaborate endoplasmic reticulum (ER).  
The ER is an essential organelle for the proper processing and folding of proteins 
such as proinsulin. Proteins fold properly when the ER protein load balances with the ER 
folding capacity that handles this load. Disruption of this ER homeostasis by genetic and 
environmental stimuli leads to an accumulation of misfolded and unfolded proteins, a 
condition known as ER stress. Upon ER stress, the unfolded protein response (UPR) is 
activated. The UPR is a signaling network that aims to alleviate ER stress and restore ER 
homeostasis promoting cell survival. Hence, the UPR allows β-cells to handle the 
physiological fluctuations of insulin demand.  
However upon severe unresolvable ER stress conditions such as during diabetes 
progression, the UPR switches to pathological outputs leading to β-cell dysfunction and 
apoptosis. Severe ER stress may also trigger inflammation and accumulating evidence 
suggests that inflammation also contributes to β-cell failure, but the mechanisms remain 
elusive.  
  In this dissertation, we demonstrate that thioredoxin interacting protein (TXNIP) 
mediates ER stress induced β-cell inflammation and apoptosis. During a DNA microarray 
analysis to identify novel survival and death components of the UPR, we identified 
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TXNIP as an interesting proapoptotic candidate as it has been linked to glucotoxicity in 
β-cells. During our detailed investigation, we discovered that TXNIP is selectively 
expressed in β-cells of the pancreas and is strongly induced by ER stress through the 
IRE1α and PERK-eIF2α arms of the UPR and specifically its transcription is regulated 
by activating transcription factor 5 (ATF5) and carbohydrate response element binding 
protein (ChREBP) transcription factors.  
 As TXNIP has been shown to activate the Nod-like receptor protein 3 (NLRP3) 
inflammasome leading to the production of the inflammatory cytokine interleukin-1β (IL-
1β), we hypothesized that perhaps TXNIP has a role in IL-1β production under ER stress. 
We show that ER stress can induce IL-1β production and that IL-1β is capable of binding 
to IL-1 type 1 receptor (IL-1R1) on the surface of β-cells stimulating its own expression. 
More importantly, we demonstrate that TXNIP does indeed play a role in ER stress 
mediated IL-1β production through the NLRP3 inflammasome. Furthermore, we also 
confirmed that TXNIP is a mediator of β-cell apoptosis under ER stress partially through 
IL-1β signaling.  
 Collectively, we provide significant novel findings that TXNIP is a component of 
the UPR, mediates IL-1β production and autostimulation, and induces cell death under 
ER stress in β-cells. It is becoming clear that TXNIP has a role in the pathogenesis of 
diabetes and is a link between ER stress, oxidative stress and inflammation. 
Understanding the molecular mechanisms involved in TXNIP expression, activity, and 
function as we do here will shed light on potential therapeutic strategies to tackle 
diabetes.  
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CHAPTER I 
INTRODUCTION 
1.1 Diabetes and pancreatic β-cells  
 Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia 
or high blood glucose levels. These diseases could lead to life threatening complications 
including kidney failure, blindness, amputations, heart disease, and stroke. Diabetes is 
one of the top ten causes of death in the United States affecting 25.8 million people or 8.3 
% of the population with economic costs totaling 174 billion dollars in 20111, 2. It is 
estimated that by 2050, 1 in 3 Americans will have diabetes. Therefore diabetes is an 
epidemic problem and research on the matter is vital in discovering methods to prevent 
and treat these diseases.  
 The two major forms of diabetes are type 1 and type 2. Type 1 diabetes is 
characterized by pancreatic β-cell loss due to autoimmunity causing an absolute 
deficiency of insulin. Type 2 diabetes accounts for 90 – 95% of all diabetes and develops 
as β-cells fail to secrete enough insulin to cope with insulin resistance. β-cells are located 
in the endocrine portion of the pancreas known as islets of Langerhans apart from the 
exocrine pancreas. These clusters of cells are largely composed of β-cells but also contain 
α-cells that secrete glucagon, δ -cells that secrete somatostatin and PP cells that secrete 
pancreatic polypeptide. All of these cells together participate in maintaining glucose 
homeostasis. The primary function of β-cells is to tightly regulate the production, storage, 
and secretion of insulin. Insulin is a hormone that functions to lower blood glucose levels. 
Upon a rise in blood glucose levels such as after eating a meal, β-cells secrete insulin and 
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stimulate insulin protein synthesis. Secreted insulin promotes blood glucose uptake by 
muscle and adipose tissues. In the muscle, glucose is either stored as glycogen or used for 
energy. In adipose tissue, glucose is stored as triglycerides and insulin prevents lipid 
degradation.  Insulin also stimulates the liver to convert glucose as glycogen while 
inhibiting glucose production3.  
 In the early stages of type 2 diabetes, overnutrition among other factors usually 
associated with obesity causes a decrease in sensitivity of peripheral tissues to insulin, a 
condition termed insulin resistance4. As a result, blood glucose levels are elevated. 
Pancreatic β-cells compensate by increasing insulin secretion. β-cells also increase 
insulin mRNA translation5, 6 and in later phases insulin transcription7. However for a 
subset of genetically predisposed individuals, β-cells can no longer compensate for this 
increased insulin demand and type 2 diabetes ensues. This β-cell failure is due to a 
combination of β-cell dysfunction and loss. Therefore disruption of β-cell integrity is a 
major component during the progression of both type 1 and type 2 diabetes. Clinical, 
genetic, and experimental evidence suggest that endoplasmic reticulum (ER) stress has a 
role in β-cell dysfunction and death8-10.  
 
1.2 The ER, ER stress, and insulin biosynthesis   
 The major function of the ER is the processing and maturation of newly 
synthesized secreted and transmembrane proteins such as insulin. The ER lumen contains 
protein processing, folding, and quality control enzymes including molecular chaperones, 
glycosylating enzymes, and oxidoreductases supported by an oxidizing and calcium-rich 
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environment to ensure the proper folding of proteins. ER chaperones aid in burying 
hydrophobic amino acids of polypeptides through ATP hydrolytic cycles of binding and 
release. Glycosylating enzymes covalently attach glycans to newly synthesized proteins. 
Supported by an oxidizing ER, oxidoreductases promote proper disulfide formation and 
rearrangements between cysteine groups.  Quality control enzymes ensure that only 
properly folded proteins are released from the ER. Misfolded proteins are recognized, 
retrotranslocated out of the ER, and delivered to the proteasome in a process termed 
endoplasmic reticulum-associated degradation (ERAD). Calcium is utilized as a cofactor 
by a majority of these enzymes.  
Proteins fold properly when the ER chemical environment and the protein folding 
machinery establishes an ER folding capacity that can efficiently handle the ER protein 
load (Figure 1.1). This balance is termed ER homeostasis. However, an array of 
environmental and genetic conditions can disrupt ER homeostasis. These factors may 
affect the ER folding capacity such as ATP or calcium depletion, ER reduction, and 
dysfunctional ER folding machinery. Other factors may affect the ER protein load such 
as an increase in mRNA translation, expression of mutant malfolding proteins, 
production of radical oxygen species (ROS), and inefficient protein trafficking. Upon the 
loss of ER homeostasis, misfolded and unfolded proteins accumulate within the ER, a 
condition referred as ER stress. 
Pancreatic β-cells are susceptible to physiological ER stress causing conditions. 
High blood glucose levels increase β-cell insulin biosynthesis in order to replenish insulin 
stores lost from insulin secretion. Human insulin is synthesized in the cytoplasm as 
  4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Endoplasmic reticulum (ER) stress. ER stress is caused by an imbalance between 
the ER protein load and the ER folding capacity that handles this load. Factors that affect the ER 
protein load include increased mRNA translation, expression of mutant malfolding proteins, 
production of radical oxygen species (ROS), and inefficient trafficking. Other factors such as 
ATP and calcium depletion, ER reduction, and defects in the ER folding machinery will affect the 
ER folding capacity. These stimuli disrupt ER homeostasis causing an accumulation of misfolded 
and unfolded proteins in the ER lumen.     
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preproinsulin. A signal peptide sequence at the N-terminal directs the protein to the ER 
where it is translocated into the ER lumen. In the ER, the signal sequence is cleaved 
producing proinsulin. Proinsulin then undergoes oxidative protein folding forming three 
disulfide bonds catalyzed by protein disulfide isomerase (PDI), ER oxidoreductase 1 α 
(ERO1α), and binding immunoglobin protein (BiP). Upon passing the ER quality control 
system, proinsulin is transported to the Golgi apparatus where it is packaged into 
secretory granules. Within these granules, proinsulin is further processed into mature 
insulin and is ready for release by exocytosis. β-cells ensure they maintain a readily 
available pool of secretory granules containing insulin in order to efficiently respond to 
high blood glucose levels11, 12. 
 
1.3 The UPR   
 Glucose stimulates over a 10-fold increase in preproinsulin translation creating a 
heavy ER protein load overwhelming the ER folding capacity and subsequently causing 
ER stress. Therefore β-cells are equipped with a highly developed ER and an extensive 
signaling network to adapt to ER stress termed the unfolded protein response (UPR) 
(Figure 1.2)13, 14. The UPR is composed of three ER transmembrane stress sensors: 
inositol requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK), and activating 
transcription factor 6 (ATF6). The luminal domains are held inactive by the ER resident 
chaperone, BiP. Under ER stress conditions, the luminal domains sense misfolded and 
unfolded proteins either directly or through the titration of BiP off onto unfolded 
proteins15. Consequently, the UPR stress tranducers are activated and communicate the  
  6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The UPR stress sensors. Upon ER stress, BiP dissociates from the luminal domains 
of the three UPR stress sensors, IRE1, PERK, and ATF6. As a result these UPR master regulators 
become activated and regulate a series of downstream effectors to mitigate ER stress and restore 
ER homeostasis. 
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ER folding status across the ER membrane to the cytosol to regulate a series of 
downstream effectors.  
Initially the UPR triggers the adaptive response to alleviate ER stress and restore 
ER homeostasis (Figure 1.3). During the early phases of the UPR, global protein 
translation is attenuated and ER associated mRNAs are degraded to reduce ER workload 
and prevent further accumulation of unfolded proteins. Shortly after, the UPR also 
increases the expression of ERAD and autophagy components to remove malfolded 
proteins. To increase the ER folding and handling efficiency, the UPR upregulates the 
transcription of molecular chaperones, protein processing enzymes and other components 
of the ER protein folding machinery. The UPR also regulates the expression of genes 
involved in lipid biogenesis to promote the expansion of the dynamically fluid ER 
membrane presumably to prevent protein crowding.    
  IRE1 is the first stress sensor discovered and is widely conserved among species. 
There are two mammalian isoforms of IRE1: IRE1α and IRE1β16, 17. IRE1α is expressed 
in most cells and highly expressed in β-cells. IRE1β is primarily expressed in intestinal 
epithelial cells. IRE1α is a type 1 ER transmembrane serine/threonine protein kinase with 
endoribonuclease activity. Upon ER stress, the N-terminal luminal domain of IRE1α 
senses ER stress either directly by binding to misfolded proteins18 or through the 
dissociation of BiP15, 19 causing IRE1α to dimerize and transautophosphorylate its kinase 
domains activating its endoribonuclease activity. Activated IRE1α specifically cleaves a 
26 nucleotide intron from the mRNA of the basic leucine zipper (b-ZIP) transcription 
factor X-box binding protein (XBP-1)20-22. This splicing event results in a translational  
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Figure 1.3 Adaptive responses. The UPR stimulates four adaptive responses: 1) alleviating the 
ER protein load, 2) removal of malfolded proteins, 3) increasing the ER folding capacity, and 4) 
expanding the ER membrane.  
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frameshift producing an active form of XBP-1. XBP-1 has a major role in the 
transcriptional regulation of several UPR homeostatic genes including those encoding 
chaperones, ERAD components, and phospholipid biosynthesis machinery23-27. IRE1α 
also cleaves ER associated mRNAs such as insulin to reduce ER workload28-30. 
 PERK is also a type 1 ER transmembrane serine/threonine protein kinase. Similar 
to IRE1α, PERK senses ER stress at its N-terminal domain, dimerizes and 
transautophosphorylates its kinase domains. Activated PERK phosphorylates serine-51 
on the α subunit of eukaryotic translation initiation factor 2 (eIF2)31. Phosphorylated 
eIF2α inhibits ribosome assembly and therefore attenuates global protein translation 
reducing ER protein load32, 33. However, translation of certain mRNAs is enhanced as the 
ribosome skips inhibitory upstream open reading frames. Examples of these mRNAs 
include activating transcription factor 5 (ATF5), cationic amino acids transporter 1 
(Cat1), and the well-characterized b-ZIP transcription factor, activating transcription 
factor 4 (ATF4)34-37. ATF4 regulates UPR genes including those encoding chaperones, 
ERAD components, amino acid homeostasis regulators, and antioxidative stress response 
effectors32, 38. 
The third ER stress sensor, ATF6, has two genes, ATF6α and ATFβ expressed in 
all cells. Studies with mouse embryonic fibroblasts deficient in ATF6α or ATF6β 
demonstrate that ATF6α has a major role in the regulation of UPR genes as opposed to 
ATF6β39, 40. However, a double knockout of murine ATF6α and ATF6β causes 
embryonic lethality indicating that ATF6α and ATF6β may have complementary 
functions important for mouse development40. ATF6α is a 90 kDa type II ER 
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transmembrane transcription factor that has a unique activation mechanism. Upon ER 
stress, BiP dissociates from ATF6α and disulfide bonds in the luminal domain are 
reduced allowing ATF6α to transit to the Golgi apparatus where it is processed by site 1 
(S1P) and site 2 (S2P) proteases.  S1P removes the luminal domain and S2P cleaves the 
transmembrane anchor producing the active 50 kDa b-ZIP transcription factor41-43. The 
cytosolic fragment of ATF6α subsequently translocates to the nucleus where it functions 
as a transcriptional activator sometimes with XBP-1 regulating ERAD components, lipid 
biosynthesis, and ER chaperones such as BiP39, 40, 44. 
 
1.4 The UPR binary switch between life and death  
 In addition to the adaptive response, the UPR also determines cell fate (Figure 
1.4). The current paradigm suggests that the UPR behaves as a binary switch between life 
and death10, 45. The consequence of this switch depends on the nature of the ER stress 
condition, the balance between UPR survival and death components, and the activation 
and regulation of the UPR stress sensors. The components and mechanisms involved in 
the UPR binary switch between life and death is cell type specific. This area remains 
poorly understood. 
 
1.4.1 The UPR under tolerable ER stress  
 There are two types of ER stress: tolerable and unresolvable. Under tolerable ER 
stress, the UPR regulates adaptive and survival components mitigating ER stress, 
restoring ER homeostasis, and promoting cell survival (Figure 1.5). β-cells regularly  
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Figure 1.4 The UPR binary switch between life and death. The UPR behaves as a binary 
switch between life and death. The consequence of this switch depends on several factors 
including the type of ER stress, the degree of UPR regulation and activation, and the regulation of 
UPR survival and death effectors. 
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Figure 1.5 The UPR under tolerable ER stress. Under mild tolerable ER stress conditions, the 
UPR favors adaptive and survival pathways that alleviate ER stress and promote cell survival. As 
ER homeostasis is being restored, the UPR is turned off by negative feedback mechanisms.  
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experience physiological stress conditions that induce tolerable ER stress such as 
fluctuations in blood glucose levels leading to an overwhelming load of proinsulin in the 
ER. The PERK branch of the UPR is vital for β-cells to handle this tolerable ER stress. 
During basal glucose conditions, phosphorylated eIF2α levels are high46, 47. However, as 
blood glucose levels increase, levels of phosphorylated eIF2α decline allowing insulin 
translation47. As proinsulin ER load increases causing ER stress, eIF2α becomes re-
phosphorylated to attenuate global translation including preproinsulin translation 
relieving the ER workload. Meanwhile ATF4 is translationally privileged and induces the 
transcription of adaptive response genes. The PERK-eIF2α pathway also induces the 
transcription of apoptosis antagonizing transcription factor (AATF)48. AATF promotes β-
cell survival partly through the transcriptional upregulation of Akt1 through signal 
transducer and activator of transcription 3 (STAT3) leading to increased levels of 
activated Akt1. Akt1 is a serine/threonine protein kinase involved in multiple cellular 
processes including promoting cell survival.  
The PERK-eIF2α pathway in particular is very important for β-cells to properly 
handle the dynamic increases of insulin biosynthesis as exemplified in genetic studies. 
Loss of function mutations in the EIF2AK3 gene encoding PERK causes the rare disorder 
known as Wolcott-Rallison syndrome which is characterized by infantile diabetes among 
other pathologies49, 50. Complications of this disease are most likely due to the fact that 
without functional PERK, eIF2α cannot be phosphorylated. Consequently, under high 
glucose conditions, insulin translation cannot be mitigated exacerbating ER stress leading 
to β-cell dysfunction and death. Indeed, PERK null mice also exhibited diabetes due to β-
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cell apoptosis caused by high levels of ER stress46, 51. Similarly, mice with a homozygous 
knock in mutation at the PERK phosphorylation site in eIF2α (Ser51Ala) demonstrated 
extensive β-cell loss due to ER stress and die shortly after birth52. Further studies of 
heterozygous Ser51Ala mice fed a high fat diet developed glucose intolerance due to a 
high level of proinsulin in the ER preventing proper insulin processing and insulin 
secretion53. Collectively, these studies demonstrate the importance of the PERK-eIF2α 
pathway to reduce preproinsulin translation in order to reduce ER workload under high 
glucose. This pause in insulin biosynthesis allows the ER machinery to properly process 
and fold proinsulin within the ER in order to maintain a steady supply of insulin to 
secrete. 
IRE1α is also activated under high glucose conditions. Under acute high glucose 
conditions, IRE1α increases the ER folding capacity through XBP-1 and promotes 
insulin biosynthesis and proinsulin folding in the ER54.  Basal levels of IRE1α mediated 
mRNA degradation may also reduce ER workload. Therefore under physiological 
changes in blood glucose levels, PERK and IRE1α are activated to relieve the increased 
ER proinsulin load while increasing the ER folding capacity to handle this load restoring 
ER homeostasis and promoting β-cell survival.  
 
1.4.2 The UPR under unresolvable ER stress 
 Unresolvable ER stress is severe and cannot be rescued by the UPR (Figure 1.6). 
Under these conditions, the adaptive and survival components of the UPR fail to achieve 
ER homeostasis. Instead the UPR is harmfully hyperactivated switching to pathological  
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Figure 1.6 The UPR under unresolvable ER stress. Under severe unresolvable ER stress, the 
UPR stress sensors bypass negative feedback mechanisms and become hyperactivated favoring 
the expression and activation of proapoptotic effectors and hampering the ER folding capacity 
leading to cell death. 
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outputs55. These outputs include the expression and activation of proapoptotic effectors, 
deterioration of the ER folding capacity, and reduction of β-cell function. For instance 
under chronic high glucose conditions, the endoribonuclease domain of IRE1α becomes 
destructive degrading important ER-associated mRNAs including ER homeostatic 
proteins BiP and PDI thus reducing the ER folding capacity and promoting cell death28. 
IRE1α also recruits the adaptor protein tumor necrosis factor receptor-associated protein 
2 (TRAF2) and together activates apoptosis signal regulating kinase 1(ASK1), which 
subsequently leads to the phosphorylation and activation of c-Jun N-terminal kinase 
(JNK)56. JNK can promote apoptosis by inactivating anti-apoptotic members of the B-cell 
lymphoma 2 (BCL-2) family members, Bcl-2, Bcl-XL and Mcl-1. JNK can also induce 
death by activating pro-apoptotic BH-3 only proteins such as Bid and Bim57. In addition 
IRE1α can trigger cell death through its association of BCL-2 family members, Bax and 
Bak, promoting IRE1α hyperactivation58. Furthermore, overproduction of spliced XBP-1 
may inhibit β-cell function and promote β-cell apoptosis59.  
 Under unresolvable ER stress conditions, PERK is also hyperactivated and induces 
β-cell dysfunction and death. Prolong translational block by phosphorylated eIF2α 
depletes cells of essential proteins for proper function and survival. The PERK-eIF2α 
pathway upregulates the translation of ATF4. ATF4 induces the transcription of 
activating transcription factor 3 (ATF3)60. ATF3 reduces transcription and activity of 
pancreatic and duodenal homeobox 1 (PDX-1)61, 62. PDX-1 is a key transcription factor in 
the proper function and survival of β-cells. Its expression is reduced during type 2 
diabetes progression. ATF3 along with ATF4 also induces the transcription of the 
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proapoptotic transcription factor, CCAAT-enhancer-binding protein (C/EBP) 
homologous protein (CHOP)60, 63, 64. CHOP plays a role in apoptosis by a number of 
possible mechanisms including regulation of the BCL-2 family members65-67, increasing 
ER radical oxygen species66, 68, and depleting ER calcium stores69, 70. Accordingly, 
CHOP deletion reduced β-cell apoptosis and improved β-cell function in several diabetic 
mouse models71, 72. 
 ATF6α also appears to have a role in the life and death decisions of the β-cell; 
however, the components and mechanisms are not clear. Basal levels of active ATF6α 
may be important in promoting β-cell survival73. Under severe ER stress conditions, 
ATF6α hyperactivation induces β-cell death partly through CHOP induction and plays a 
role in β-cell dysfunction by decreasing insulin gene expression74. ATF6α is also 
hyperactivated in Wolfram syndrome due to the lack of functional WFS1 and therefore 
may play a role in β-cell death in these patients75. Furthermore, ATF6α variants have 
been associated with type 2 diabetes in human genetic studies76, 77. ATF6α-null mice do 
not display any defects in β-cell function or loss in β-cell mass on a normal chow diet. 
However, recently it was reported that on a high fat diet, β-cells in these mice experience 
severe ER stress with reduced insulin content most likely due to increased β-cell 
apoptosis78. These results suggest that ATF6α has an important role in mitigating ER 
stress promoting β-cell survival under obese conditions. 
 The UPR survival and death components are also regulated at the post-
transcriptional level79. During tolerable ER stress conditions, the stabilities of mRNAs 
and proteins that favor survival and adaptation such as BiP are enhanced whereas those 
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involved in apoptosis such as CHOP are compromised. Under unresolvable ER stress, 
proapoptotic components are expressed at high levels bypassing any negative regulation. 
The mechanisms of mRNA instabilities may involve IRE1α mediated mRNA 
degradation or UPR regulated miRNAs. It would be interesting to investigate the 
stabilities of UPR mRNAs and proteins in β-cells under tolerable and unresolvable ER 
stress conditions.  
 
1.4.3 Negative feedback mechanisms of the UPR 
As discussed, the UPR switches between life and death depending on the severity 
of the ER stress and the subsequent regulation of both survival and death effectors. The 
outcome of this switch also depends on the tight regulation of the UPR signal transducers 
themselves. Under tolerable ER stress conditions, the UPR stress sensors and 
downstream effectors are negatively regulated by feedback control mechanisms as ER 
homeostasis is restored (Figure 1.5). However during unresolvable ER stress conditions, 
the UPR stress sensors bypass these control mechanisms leading to harmful UPR 
hyperactivation promoting cell death. The effectors involved in UPR signaling regulation 
are the very UPR switches between life and death.  Nonetheless, the components and 
mechanisms of this feedback regulation during mild and severe ER stress remain elusive.  
One possible feedback mechanism may involve the ER resident chaperone BiP. 
As mentioned previously, BiP binds to the luminal domains of the UPR transducers 
keeping them inactive. Upon ER stress, BiP is released to participate in protein folding, 
which allows for activation of the UPR stress sensors. During the UPR, BiP is also 
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transcriptionally upregulated promoting the binding of BiP to the UPR master regulators 
therefore restricting their activities.  
Another mechanism involves phosphatases that function to dephosphorylate 
certain components of the UPR. Under ER stress, ATF4 and CHOP upregulate the 
transcription of growth arrest and DNA damage-inducible protein 34 (GADD34)80-83. 
GADD34 interacts with protein phosphatase I (PP1) to desphosphorylate eIF2α. 
Consequently, protein translation is restored and the PERK branch of the UPR is turned 
off. A similar mechanism has been proposed for IRE1α dephosphorylation by protein 
phosphatase 2A (PP2A) recruited by the scaffolding protein receptor for activated C-
kinase 1 (RACK1)84. 
Another regulator of the PERK pathway is the chaperone, protein kinase inhibitor 
of 58 kDa (p58ipk). Under ER stress, ATF6α induces p58ipk transcription85. p58ipk binds to 
PERK and inhibits its ability to phosphorylate eIF2α therefore restoring protein 
translation85, 86. As the PERK-eIF2α pathways is important for β-cell function and 
survival, p58ipk deletion mice develop hyperglycemia with a decrease in β-cell mass due 
to apoptosis perhaps by severe ER stress as a result of the inability to attenuate insulin 
translation87. p58ipk may also function as a cochaperone with BiP in the ER lumen to 
assist in protein folding88, 89 or with heat shock protein 70 (HSP70) in the cytoplasm at 
ER translocans to degrade newly synthesized ER-targeted proteins90. 
Upon ER stress homeostasis restoration, ATF6α is also under negative regulation 
by Wolfram syndrome I (WFS1)75. WFS1 is an ER transmembrane protein and has 
important roles in maintaining the ER including regulating ER calcium levels and the 
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UPR. Under non-stressed conditions, WFS1 recruits ATF6α to the E3 ubiquitin ligase 
HRD1 and the proteasome for ubiquitin-mediated degradation therefore preventing 
ATF6α activation. Under stressed conditions, ATF6α dissociates from WFS1 in order to 
upregulate adaptive response genes in the nucleus. As ER homeostasis is being restored, 
WFS1 expression is induced by the IRE1α and PERK pathways promoting WFS1 to 
negatively regulate ATF6α.  Mutations in the WFS1 gene causes Wolfram syndrome, a 
rare autosomal recessive neurodegenerative disorder characterized by juvenile onset 
diabetes, optic atrophy, and deafness91. Analysis of pancreatic islets of Wolfram 
syndrome patients demonstrate β-cell loss92. β-cell loss may be caused by apoptosis as a 
result of ATF6α hyperactivation due to the lack of WFS1 negative feedback. Likewise, 
downregulation of WFS1 in β-cell lines exhibited high ER stress levels causing β-cell 
dysfunction and death. Furthermore, WFS1 knockout mice and β-cell specific WFS1 
knockout mice also develop diabetes due to ER stress-induced β-cell apoptosis93, 94. It 
would be beneficial to study the genes regulated by hyperactivated ATF6α that may 
promote β-cell death.  
 
1.5 β-cell specific ER stress inducers  
 Causes of ER stress and the activated UPR program are cell-type specific. Besides 
the dynamic changes in extracellular glucose, there are other environmental and genetic 
factors that induce ER stress specifically in β-cells (Figure 1.7). Many of these stimuli 
induce unresolvalable ER stress during the progression of diabetes leading to β-cell 
death. Elevated levels of free fatty acids due to diet and obesity have a role in β-cell  
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Figure 1.7 β-cell specific ER stress inducers. β-cells are susceptible to a variety of ER stress 
inducers including high glucose, human islet polypeptide (hIAPP), cytokines, free fatty acids and 
expression of mutant malfolding insulin. These conditions are capable of triggering unresolvable 
ER stress causing β-cell dysfunction and death.    
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failure during type 2 diabetes. Exposure of β-cells to the saturated free fatty acid, 
palmitate, causes ER stress activating all three arms of the UPR95, 96. Palmitate creates ER 
stress through inhibiting sarcoplasmic endoplasmic reticulum calcium-ATPase (SERCA) 
pump activity depleting ER calcium97, 98 and disrupting ER-to-Golgi protein trafficking 
causing an overload of proteins in the ER99. Palmitate also causes carboxypeptidase E 
degradation leading to an accumulation of unprocessed proinsulin100. Palmitate has a role 
in lipotoxicity of β-cells by inducing the expression of CHOP and activating JNK97, 101.   
 Proinflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α 
(TNF-α), and interferon-γ (IFN-γ) secreted from invasive immune cells are the major 
mediators of β-cell dysfunction and apoptosis during the progression of type 1 
diabetes102-104. It has been proposed that cytokines induce ER stress contributing to β-cell 
dysfunction and demise105-108. However, the mechanisms remain to be clarified due to 
experimental differences.  The general model suggests that cytokines activate the 
transcription factor nuclear factor-κB (NF-κB), which has a major role in regulating the 
transcription of proapoptotic genes including nitric oxide synthase leading to nitric oxide 
(NO) production. NO downregulates SERCA2b expression leading to depletion of ER 
calcium levels and therefore causing ER stress. Another report suggest that NO may 
instead stimulate the expression of UPR proapoptotic components such as CHOP, while 
decreasing expression of adaptive effectors109. Additional studies are required to clarify 
contradictory results.  
 The major function of β-cells is to produce and secrete insulin. If the insulin gene 
is mutated causing misfolding in the ER, severe ER stress is induced leading to β-cell 
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apoptosis. This idea is demonstrated in Akita mice71, 110. These mice express a mutated 
form of insulin 2 in which a cysteine is substituted for tyrosine at position 96 (C96Y). 
This mutation disrupts one of the three disulfide bonds between the A and B chains of 
mature insulin. Consequently, these mice develop diabetes due to high levels of ER stress 
in their β-cells leading to β-cell dysfunction and death. In the β-cells of Akita mice, the 
ER is distended, a hallmark of ER stress. Also ER stress markers, BiP and CHOP are 
upregulated.  Furthermore, mRNA levels are reduced probably due to IRE1α 
hyperactivation.  Likewise, human genetic studies revealed several mutations in the 
insulin gene related to proper proinsulin folding that are linked to neonatal diabetes111, 112. 
One such mutation is identical to the mutation found in the Akita mice113. 
Islet amyloid deposits are commonly found in the patients of type 2 diabetes and 
are linked to β-cell dysfunction and death. These amyloid formations are composed of 
aggregated islet amyloid polypeptide (IAPP). Even though controversial114, IAPP may 
form amyloid sheets that damage the ER causing severe ER stress and β-cell death 
perhaps by impairing the ubiquitin-proteasome pathway. Islets of mice overexpressing 
the amyloidogenic human IAPP (hIAPP) demonstrated an increase in ER stress markers 
such as XBP-1 and CHOP, and an accumulation of polyubiquitinated proteins as opposed 
to islets from mice expressing rat IAPP115, 116. Similar findings were found in hIAPP 
treated mouse insulinoma MIN6 cells and isolated human pancreatic islets117. 
  
1.6 The UPR interconnects with oxidative stress and inflammation  
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The UPR is also capable of inducing other cellular stresses and crosstalking with 
signaling pathways. For instance in order for proinsulin to fold properly, the ER must 
coordinate proper formation of 3 disulfide bonds. During this oxidative protein folding, 
ROS is produced118-121. β-cells in particular are sensitive to ROS production due to their 
lack of antioxidant proteins such as catalase and glutathione peroxidase122, 123. When 
blood glucose rises, causing an increase in proinsulin ER load, high levels of ROS could 
be produced. In addition, ER stress causes calcium leakage from the ER to the 
mitochondria stimulating mitochondria mediated ROS production124-126. In turn, ROS 
could increase ER stress by modifying ER protein and lipids important in establishing ER 
homeostasis. Furthermore, ROS production has a major role in glucotoxicity of β-cells127, 
128. Therefore ROS generated by ER stress could also have a role in glucotoxicity.  
 It has been suggested that the UPR could also trigger inflammation (Figure 
1.8)129-131. For instance, all three arms of the UPR have been proposed to be involved in 
the activation of NF-κB, which regulates genes involved in apoptosis and the 
inflammatory response such as cytokines. IRE1α together with TRAF2 binds to and 
activates inhibitory κB kinase (IKK)132. IKK phosphorylates the NF-κB inhibitor IκB 
leading to its degradation. Subsequently, NF-κB is released and free to translocate into 
the nucleus to regulate transcription. The PERK-eIF2α pathway suppresses translation of 
IκB, which promotes NF-κB activation133, 134. It has also been suggested that ATF6α can 
activate NF-κB through phosphorylation of Akt135. IRE1α also activates JNK, which can 
also influence expression of inflammatory genes through the phosphorylation of the  
 
  25  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 ER stress and inflammation. The UPR is capable of intersecting with inflammatory 
signaling. For instance, all three ER stress sensors can activate NF-κb, a key inflammatory 
transcription factor. IRE1α can also activate JNK, which in turn can activate inflammatory 
transcription factors such as AP-1. Furthermore, it has been recently reported that the NLRP3 
inflammasome associates with the ER and can be activated upon ER stress conditions leading to 
IL-1β secretion.  
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transcription factor, activator protein 1 (AP-1)56. Recently it has been reported that 
inactive Nod-like receptor protein 3 (NLRP3) inflammasome associates with the ER and 
upon activation relocates to mitochondria-associated ER membranes (MAMs)136, contact 
sites in which the ER transfers signals to the mitochondria to induce cell death137, 138. 
Furthermore, ER stress can activate the NLRP3 inflammasome139. The NLRP3 
inflammasome is responsible for the processing and activation of the proinflammatory 
cytokine, IL-1β.  Collectively, these observations suggest that ER stress could induce 
expression of inflammatory components and secretion of IL-1β potentially leading to 
inflammation. 
 
1.7 Inflammation in diabetes  
Inflammation is a contributing factor of β-cell destruction in type 1 diabetes and 
accumulating evidence links inflammation to the pathogenesis of type 2 diabetes140, 141. 
Several changes of the immune system can be detected in patients with type 2 diabetes 
such as elevated circulating cytokines and chemokines. The production and secretion of 
these cytokines and chemokines stem from several sources including β-cells as a result of 
metabolic overload. β-cells production and secretion of these inflammatory components, 
especially the cytokine IL-1β has been shown to play a key role in β-cell loss during type 
2 diabetes.  
The mechanism of IL-1β production involves the interaction of thioredoxin 
interacting protein (TXNIP) with the NLRP3 inflammasome142. In β-cells, TXNIP, a 
member of the α-arrestin protein family, is transcriptionaly upregulated by high glucose 
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mediated by the transcription factors carbohydrate response element-binding protein 
(ChREBP) and Max-like protein X (Mlx) binding to carbohydrate-response elements 
(ChoREs)143-146. TXNIP directly binds to and inhibits the antioxidative protein 
thioredoxin causing an increase in intracellular ROS147-149. Thioredoxin also interacts and 
inhibits a number of apoptotic effectors such as ASK-1 and NF-κb.  Therefore glucose-
induced TXNIP expression causes oxidative stress leading to β-cell death. In addition, 
during high glucose conditions, ROS causes TXNIP to dissociate from thioredoxin. 
Liberated TXNIP binds to and activates the NLRP3 inflammasome leading to caspase-1 
activation, which processes IL-1β into its active form. As β-cells secrete activate IL-1β, it 
can act upon the highly expressed IL-1 receptor type 1 (IL-1R1) on β-cells, inducing the 
expression of itself as well as chemokines through the transcription factor NF-κB. 
Meanwhile, macrophages are recruited to islets eliciting a broad inflammatory response. 
IL-1β and other cytokines can also induce ER stress and activate apoptotic pathways 
leading to β-cell death (Figure 1.9). This vicious cycle of autoinflammation may be 
enhanced in type 2 diabetes patients that carry a genetic variation in a gene encoding the 
endogenous IL-1β antagonist, IL-1 receptor antagonist (IL-1RA)150. 
 
1.8 Summary of Thesis Research: TXNIP mediates autoinflammation and apoptosis 
in β-cells under ER stress  
Taken together, ER stress is triggered by an array of stimuli leading to the 
activation of the UPR. During mild tolerable ER stress conditions, adaptive responses are 
capable of mitigating ER stress and restoring ER homeostasis. Subsequently, the UPR is  
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Figure 1.9 Islet inflammation. Under high glucose conditions, ROS is produced promoting the 
antioxidant protein thioredoxin to release TXNIP. Consequently, TXNIP binds to and activates 
the NLRP3 inflammasome leading to the processing and secretion of active IL-1β. IL-1β in turn 
can bind to the IL-1 receptor type 1 (IL-1R1) on the surface of β-cells inducing the expression of 
itself and chemokines through NF-κB.  Meanwhile, macrophages are recruited to islets eliciting a 
broad inflammatory response.  
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properly downregulated fostering β-cell function and survival. However, under severe 
unresolvable ER stress conditions, the UPR becomes hyperactivated promoting the 
activation of apoptotic pathways, inducing ROS production, and intersecting with 
inflammatory signaling leading to β-cell dysfunction and death contributing to diabetes 
development.  
We are interested in identifying the survival and death components regulated by 
the UPR and the mechanisms involved in the UPR binary switch between life and death 
in the context of the β-cell. To this end, we focused on studying genes regulated by the 
anti-apoptotic UPR transcription factor AATF. During a DNA microarray analysis of 
genes differentially expressed by the overexpression of AATF in the rat insulinoma cell 
line INS-1 832/13, we have identified a potential novel apoptotic UPR component, 
TXNIP. Interestingly during our detailed investigation of TXNIP, we discovered that 
TXNIP mediates ER stress induced β-cell inflammation and apoptosis. 
Here we show that TXNIP is mainly expressed in β-cells of the pancreas and its 
expression is upregulated by both pharmacological and physiological ER stress inducers 
under the IRE1α and PERK-eIF2α signaling pathways of the UPR. TXNIP transcription 
is significantly upregulated by ER stress and while studying the potential transcription 
factors involved, we have identified ATF5 and ChREBP.  Because it has been 
demonstrated that TXNIP contributes to IL-1β production, we explored if TXNIP has a 
role in IL-1β production by ER stress. We demonstrated that TXNIP does indeed have a 
role in IL-1β production through the NLRP3 inflammasome and that this IL-1β is 
capable of autostimulation through IL-1R1 in β-cells under ER stress. Furthermore, we 
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confirmed that TXNIP has a role in ER stress-mediated β-cell apoptosis partly through 
IL-1β signaling. Collectively, these results suggest that ER stress and the UPR induce 
autoinflammation and β-cell death by transcriptionally upregulating TXNIP expression 
leading to IL-1β secretion and autostimulation (Figure 1.10). Therefore TXNIP promises 
to be a potential drug target in the treatment of diabetes.   
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Figure 1.10 Summary of thesis research. We have discovered that TXNIP is transcriptionally 
upregulated under the PERK-eIF2α and IRE1α arms of the UPR through the transcription factors 
ChREBP and ATF5. TXNIP activates the NLRP3 inflammasome leading to the secretion of IL-
1β. IL-1β is capable of autostimulation through IL-1R1, inducing a broad inflammatory response, 
and mediating β-cell death. 
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CHAPTER II 
THE ROLE OF TXNIP IN ER STRESS-MEDIATED IL-1β  PRODUCTION AND 
CELL DEATH IN β-CELLS 
Summary 
 Pancreatic β-cells are designed to efficiently synthesize and secrete insulin in 
response to blood glucose levels. In order to manage insulin biosynthesis, β-cells have an 
especially dynamic endoplasmic reticulum (ER). The main function of the ER is to 
process and fold proteins such as proinsulin. Proinsulin folds properly when the ER 
protein folding capacity and ER protein load are in balance, a condition referred to as ER 
homeostasis. However, genetic and environmental stimuli can disrupt ER homeostasis 
leading to an accumulation of unfolded proteins. This ER stress activates the unfolded 
protein response (UPR), a signaling network that functions to reduce ER stress and 
restore ER homeostasis. Therefore the UPR allows β-cells to handle the fluctuations of 
insulin demand. However, if ER stress is severe such as during diabetes progression, the 
UPR induces β-cell dysfunction and death. Severe ER stress may also trigger 
inflammation and evidence suggests that inflammation also plays a role in β-cell failure, 
but the mechanisms remain unclear. Here we provide evidence that thioredoxin 
interacting protein (TXNIP) mediates ER stress-induced β-cell inflammation and death. 
TXNIP expression is induced by ER stress through the IRE1α and PERK-eIF2α branches 
of the UPR and transcriptionally regulated by activating transcription factor 5 (ATF5) 
and carbohydrate response element binding protein (ChREBP). TXNIP regulates the 
production of the inflammatory cytokine interleukin 1 β (IL-1β) through the Nod-like 
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receptor protein 3 (NLRP3) inflammasome and IL-1β is capable of autostimulation 
through IL-1 receptor type 1 (IL-1R1) in β-cells under ER stress. Furthermore, TXNIP 
induces β-cell apoptosis partly through IL-1β signaling. Therefore TXNIP is a potential 
drug target for preventing β-cell failure in diabetes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  34  
Introduction 
 
 Type 2 diabetes is characterized by hyperglycemia as a result of insulin resistance 
and relative insulin deficiency4. In the early stages of type 2 diabetes, insulin becomes 
ineffective at lowering blood glucose levels. Pancreatic β-cells respond to insulin 
resistance by increasing insulin production and secretion. However for a subset of 
genetically predisposed individuals, β-cells can no longer compensate for this increased 
insulin demand and type 2 diabetes ensues. This β-cell failure is due to a combination of 
β-cell dysfunction and apoptosis. Accumulating evidence suggests that endoplasmic 
reticulum (ER) stress may contribute to β-cell failure8, 9. 
 Pancreatic β-cells are designed to efficiently synthesize, store, and secrete insulin, 
a hormone that lowers blood glucose levels. When blood glucose levels rise, β-cells 
immediately secrete insulin from an available pool and dramatically increase insulin 
biosynthesis. In order to manage this insulin demand, β-cells contain a specialized ER. 
The ER houses an elaborate enzymatic machinery supported by a unique chemical 
environment to properly process and fold proinsulin. Proinsulin folds correctly when the 
ER protein folding capacity and ER protein load are in balance. β-cells are susceptible to 
conditions such as elevated levels of blood glucose that can disrupt this ER homeostasis 
leading to an accumulation of misfolded and unfolded proinsulin, a condition referred to 
as ER stress. In order for β-cells to adapt to this ER stress, the unfolded protein response 
(UPR) is activated13. This signaling network functions to mitigate ER stress and restore 
ER homeostasis.   Therefore β-cells depend on the UPR in order to function properly. 
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 The UPR is composed of three ER stress sensors: Inositol Requiring Enzyme 1 
(IRE1), PKR-like ER kinase (PERK), and Activating Transcription Factor 6 (ATF6). 
Upon ER stress, these stress sensors become activated triggering the adaptive response 
attenuating protein translation and enhancing mRNA degradation to reduce the ER 
protein load, upregulating the transcription of protein folding and processing enzymes to 
increase the ER folding capacity, and inducing the expression of ER-associated protein 
degradation (ERAD) and autophagy components to remove malfolded proteins. 
 The UPR also determines β-cell fate behaving similar to a binary switch between 
life and death10, 45. The consequence of this switch depends on the nature of the ER stress 
condition, the balance between UPR death and survival components, and the activation 
and regulation of UPR signaling. Under healthy changes in blood glucose levels as 
discussed, the UPR can successfully mitigate this mild ER stress with the adaptive 
response and together with the increased expression of anti-apoptotic factors promote β-
cell survival. As ER homeostasis is restored, negative feedback mechanisms turn off UPR 
signaling.   However, under severe ER stress conditions such as chronic levels of glucose, 
free fatty acids, and cytokines, the UPR fails to restore ER homeostasis. Instead, the UPR 
bypasses negative regulation and becomes hyperactivated inducing the expression and 
activation of proapoptotic components leading to β-cell death. ER stress-mediated β-cell 
death has a role in the pathogenesis of type 2 diabetes.  
 ER stress and the UPR may also crosstalk with the inflammatory response to 
induce β-cell loss but a clear link has not been reported129-131. Several studies suggest that 
inflammation participates in the pathogenesis of type 2 diabetes141. β-cells are capable of 
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producing and secreting the inflammatory cytokine, interleukin-1β (IL-1β) under 
metabolic stress. In turn, secreted IL-1β is capable of autostimulation by binding to the 
highly expressed IL-1 receptor type 1 (IL-1R) on the β-cell surface. During this vicious 
cycle, IL-1β stimulates the production of itself and chemokines therefore recruiting 
macrophages to pancreatic islets leading to β-cell inflammation and death. 
 In this study, we provide evidence that thioredoxin interacting protein (TXNIP) 
induces ER stress-mediated IL-1β production and cell death in β-cells. During a DNA 
microarray analysis of UPR survival and death components regulated by the UPR anti-
apoptotic transcription factor, apoptosis-antagonizing transcription factor (AATF), we 
identified TXNIP as a potential proapoptotic component. We discovered that TXNIP is 
strongly induced by ER stress through the IRE1α and PERK-eIF2α arms of the UPR and 
specifically its transcription is regulated by activating transcription factor 5 (ATF5) and 
carbohydrate response element binding protein (ChREBP). It has been demonstrated that 
TXNIP activates the Nod-like receptor protein 3 (NLRP3) inflammasome leading to the 
production and secretion of IL-1β. Therefore we hypothesized that ER stress induces IL-
1β production through this TXNIP-NLPR3 pathway. We demonstrated that TXNIP does 
indeed have a role in IL-1β production through the NLRP3 inflammasome and that this 
IL-1β is capable of autostimulation in β-cells under ER stress. We confirmed that TXNIP 
is an apoptotic component of the UPR partly through IL-1β signaling. Collectively, these 
results suggest that the UPR can induce β-cell inflammation and apoptosis through 
TXNIP. Therefore TXNIP is a potential therapeutic target for the treatment of type 2 
diabetes. 
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Materials and Methods 
 
Cell culture and transfection of small interfering RNA 
Rat insulinoma cells, INS-1 832/13, were a gift from Dr. Christopher Newgard 
(Duke University Medical Center). These cells were cultured in RPMI 1640 
supplemented with 10% FBS, 1% sodium pyruvate, and 0.1 % 2-mercaptoethanol. Mouse 
islets were cultured in RPMI 1640 supplemented with 5% FBS and 5 mM glucose. 
Human islets (Prodo Laboratories, Irvine, CA) were cultured in CMRL media 
supplemented with 5 mM glucose and grown on laminin V coated plates. Mouse 
embryonic fibroblasts were maintained in DMEM with 10% FBS. Ireα-/- and Perk-/- 
fibroblasts were a gift from Dr. David Ron (University of Cambridge). Atf6α-/-, eIF2αS/S 
and eI2F2αA/A fibroblasts were gifts from Dr. Randal Kaufman (Sanford-Burnham 
Medical Research Institute).  
The Cell Line NucleofectorTM kit V and the NucleofectorTM Device (Lonza, 
Walkersville, MD) was used to transfect small interfering RNA (siRNA) directed against 
IRE1, PERK, ATF6, ChREBP, ATF5 and NLRP3 into INS-1 832/13 cells. siRNAs were 
designed and synthesized at QIAGEN (Valencia, CA) as follows: rat IRE1 
AAGCAGCAGACUUUGUCAUCA, rat PERK GGAAAUAUUUGGAACGAUC, rat 
ATF6 GCACAUGAGACUUACGAAA, , rat ChREBP 
AAAGGUUGUGGGUGCAGGAAGGGUA, rat ATF5 CAGAGUCAGUGGAACGGGA 
and rat NLRP3 GAGCAGCAGGCAUCGGAAA. Cells were incubated in media 
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overnight after siRNA transfection, and then additional treatments were performed, 
including ER stress induction. 
 
Isolating islets from mouse pancreata 
Mice were anesthetized by intraperitoneal injection of sodium pentobarbital. 
Pancreatic islets were then isolated by pancreatic duct injection of 500 U/mL of 
collagenase solution followed by digestion at 37°C for 40 min with mild shaking. Islets 
were washed several times with Hank’s buffered salt solution (HBSS), separated from 
acinar cells on a discontinuous Ficoll 400 gradient, viewed under a dissecting 
microscope, and hand-selected. 
 
GeneChip Array Analysis  
INS-1 832/13 cells were stably transduced with LV-TO/AATF, an inducible 
lentivirus expressing AATF. Cells were cultured with or without 2 µg/mL doxycycline to 
induce AATF for 48 h. Total RNA was isolated from samples of three independent 
experiments using RNeasy Mini Kit (Qiagen, Valencia, CA) and processed for GeneChip 
analysis by the Genomic core facility at University of Massachusetts Medical School 
(Worcester, MA). The final product was hybridized to the GeneChip® Rat Genome 230 
2.0 Arrays (Affymetrix, Santa Clara, CA) and scanned with a GeneChip Scanner 3000. 
RMA method151 in Affy package from Bioconductor was used in R to summarize 
the probe level data and normalize the dataset to remove across array variation. Log 
transformed data was used in the subsequent analysis. Limma package from 
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Bioconductor with randomized complete block design was used to determine whether 
overexpressing AATF alters a gene¹s expression level significantly. Genes with p-value < 
0.01 and at least one treatment has all three replicates called present from the mas5 
Present/Absent call was considered significant. 
 
Immunostaining 
Frozen sections of C57BL/6 mouse pancreata were fixed in 2% paraformaldehyde 
for 30 min at room temperature and then permeabilized with 0.1% Triton X-100 for 2 
min. The fixed cells were washed with phosphate-buffered saline, blocked with 10% 
bovine serum albumin for 30 min, and incubated in primary antibody overnight at 4°C. 
The cells were washed three times in phosphate-buffered saline/Tween 0.1% and 
incubated with secondary antibody for 1 h at room temperature. Images were obtained 
with a Leica TCS SP2 AOBS confocal microscope with LCS software. The following 
primary antibodies were used: anti-insulin (Dako, Carpinteria, CA), anti-glucagon (Dako, 
Carpinteria, CA), and anti-TXNIP (MBL, Nagoya, Japan). 
 
Lentivirus system  
For generation of cells stably suppressing TXNIP, INS-1 832/13 cells were 
transduced with a retrovirus expressing shRNA against rat TXNIP. The following shRNA 
oligos were used: 
GATCCCCAGCATGGCTAGCCGGACATTCAAGAGATGTCCGGCTAGCCATGCT
GTTTTTGGAAA  and 
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AGCTTTTCCAAAAACAGCATGGCTAGCCGGACATCTCTTGAATGTCCGGCTA
GCCATGCTGGG. Details of this lentivirus system were described previously 152.  
 
Plasmids 
Entry vectors, destination vectors, and viral plasmids for establishing lentiviral 
and retroviral cell lines were provided by E. Campeau 152. TXNIP reporter plasmids were 
constructed by inserting TXNIP promoter sequences into pGL4.17 (Promega, Madison, 
WI). 
 
Immunoblot  
Cells were lysed in M-PER buffer (Pierce, Rockford, IL) containing a protease 
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) for 10 min on ice. The lysates were 
then cleared by centrifuging the cells at 14,000 g for 10 min at 4°C. Lysates were 
normalized for total protein (30 µg per lane), separated using a 4-20% linear gradient 
SDS-PAGE (BioRad, Hercules, CA) and electroblotted. Blots were probed with the 
following antibodies: anti-TXNIP (MBL, Nagoya, Japan), anti-CHOP (Pierce, Rockford, 
IL), anti-eIF2α (Santa Cruz Biotechnology, Santa Cruz, CA), anti-eIF2α-P (Cell 
Signaling, Danvers, MA) and anti-actin (Sigma-Aldrich, St. Louis, MO).  
 
Real-time polymerase chain reaction 
Total RNA was isolated from the cells using RNeasy Mini Kit (Qiagen) and 
reverse transcribed using 1 µg of total RNA from cells with Oligo-dT primer. For the 
  41  
thermal cycle reaction, the iQ5 system (BioRad, Hercules, CA) was used at 95°C for 10 
min, then 40 cycles at 95°C for 10 sec and at 55°C for 30 sec. 
 The relative amount for each transcript was calculated by a standard curve of 
cycle thresholds for serial dilutions of cDNA samples and normalized to the amount of β-
actin. The polymerase chain reaction (PCR) was performed in triplicate for each sample, 
after which all experiments were repeated twice. The following sets of primers and Power 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) were used for 
real-time PCR: human actin, ACCATGGATGATGATATCGCC and 
GCCTTGCACATGCCGG; human TXNIP, CAGCCAACAGGTGAGAATGA and 
TTGAAGGATGTTCCCAGAGG; human IL-1β, CTCGCCAGTGAAATGATGGCT 
and GTCGGAGATTCGTAGCTGGAT; human IL-6, 
AAATTCGGTACATCCTCGACGG and GGAAGGTTCAGGTTGTTTTCTGC; mouse 
actin, GCAAGTGCTTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC; 
mouse TXNIP, TATGTACGCCCCTGAGTTCC and GCTCACTGCACGTTGTTGTT;  
rat actin, GCAAATGCTTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC; 
rat TXNIP, CAAGTTCGGCTTTGAGCTTC and ACGATCGAGAAAAGCCTTCA; rat 
IL-1β, CTCTGTGACTCGTGGGATGA and CGAGGCATTTTTGTTGTTCA, rat IL-6, 
TAGTCCTTCCTACCCCAACTTCC and TTGGTCCTTAGCCACTCCTTC. 
 
Luciferase Assay 
For reporter assays, INS-1 832/13 cells were cotransfected with a TXNIP 
promoter-luciferase reporter construct and various constructs as indicated by 
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Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 6 h the culture medium was 
changed to fresh medium with 2.5 mM glucose. Prior to lysis at 24 h after transfection, 
cells were treated with or without 0.5 µM of thapsigargin for 6 h. Luciferase activity was 
measured with a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and 
transfections were normalized with the pRL-TK vector (Promega, Madison, WI) as an 
internal control. The light produced from the samples was read by a standard plate 
reading luminometer. The assays were performed independently three times. 
 
Chromatin Immunoprecipitation 
ChIP was performed using the SimpleChIP™ Enzymatic Chromatin IP Kit 
(Agarose Beads) (Cell Signaling, Beverly, MA) according to the manufacturer's 
instructions. Briefly, INS-1 832/13 cells were cultured for 6 h with or without 0.5 µM 
thapsigargin and crosslinked with 1% formaldehyde. DNA was isolated using lysis buffer 
and sonicated on ice for 20 seconds with intervals of 30 seconds and repeated for 15 
cycles (Bioruptor, Denville, NJ). Chromatin immunoprecipitation was performed with the 
ChREBP (sc-21189), Mlx (sc-14705), ATF5 (sc-99205) antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA) as well as rabbit IgG as a negative control. Q-PCRs 
were performed using human TXNIP promoter-specific primers: 
CCGAACAACAACCATTTTCC and CTCCCATTGGCTACTTGGTC. 
 
Fluorescence-activated cell sorting 
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For flow cytometry analyses, INS-1 832/13–TetR-shTXNIP cells were plated 
onto 6-well plates and incubated with 2 µg/mL doxycycline for 48 h, then treated with or 
without 10 nM thapsigargin for 24 h. The treated cells were harvested and stained with 
Mitoprobe DilC1(5) kit (Invitrogen, Carlsbad, CA) and propidium iodide solution 
(Invitrogen) following manufacturer’s protocols. After washing with PBS, the stained 
cells were resuspended in the 11 mM glucose-Hanks buffered salt solution. Flow 
cytometry analyses were performed with LSRII (BD) at the FACS core facility of 
University of Massachusetts Medical School (Worcester, MA). The results were analyzed 
by FlowJo ver.7.6.3. 
 
Cell Viability Assay 
Cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Madison, WI) as per manufacturer’s instructions.  
 
Caspase-Glo 3/7 Assay  
 Apoptosis was assessed using the Cell-Glo 3/7 assay (Promega, Madison, WI) as 
per manufacturer’s instructions.  
 
Reagents 
Glucose,? palmitate, Brefeldin A, thapsigargin, and tunicamycin were obtained 
from Sigma-Aldrich (St. Louis, MO) and Cell Signaling Technology (Danvers, MA). 
RPMI-1640, DMEM, HBSS, Mitoprobe DilC1(5) kit and propidium iodide solution were 
  44  
obtained from Invitrogen (Carlsbad, CA). Human amylin (hIAPP) was ordered from 
Bachem (Torrance, CA). Human recombinant interleukin-1 receptor antagonist was 
obtained from Prospec (East Brunswick, NJ).  
 
Animal Experiments 
Txnip knockout mice were generated as previously described153. All animal 
experiments were performed according to procedures approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts Medical School. 
 
Statistical analysis 
 To calculate the significance of a difference deviation between two means, we 
used the Mann-Whiney test, unequal variance t-test, and two-way ANOVA. A p-value of 
<0.05 was considered statistically significant.  
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Results 
Gene expression profiling of β-cells overexpressing AATF reveals a novel UPR 
component TXNIP 
Upon ER stress, the UPR transcriptionally regulates both survival and death 
effectors; however, the identification of these components remains incomplete. Our lab 
has identified a novel UPR anti-apoptotic transcription factor, AATF regulated by the 
PERK-eIF2α pathway48. AATF can promote cell survival through the transcriptional 
regulation of survival and death effectors154, 155. Indeed we revealed that AATF protects 
β-cells from ER stress in part by upregulating the transcription of the survival factor, 
Akt1 with STAT3. In order to identify other transcriptional targets of AATF, we studied 
genes differentially expressed in the rat insulinoma cell line, INS-1 832/13 
overexpressing AATF by DNA microarray analysis. We screened the genes differentially 
expressed for their relation to survival or cell death and chose to focus on the apoptotic 
factor TXNIP, which was modestly downregulated by AATF (Figure 2.1a). TXNIP was 
first identified as a binding partner of thioredoxin inhibiting its protein-reducing 
activity147-149. Later it was discovered in a DNA microarray study that TXNIP expression 
was most strongly induced by glucose in isolated human islets156. Interestingly, TXNIP 
has a negative role in pancreatic β-cells including inhibiting glucose stimulated insulin 
secretion (GSIS)157, 158 and promoting glucose-mediated β-cell death159. In response to 
the latter, we speculated that perhaps TXNIP triggers β-cell death under ER stress 
conditions. We further confirmed that TXNIP was downstream of AATF by Q-PCR.  
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Figure 2.1 Gene expression profiling of INS-1 832/13 cells overexpressing AATF reveals a 
novel UPR component, TXNIP. (A) INS-1 832/13 cells were stably transduced with LV-
TO/AATF, an inducible lentivirus expressing AATF. Cells were cultured with or without 
doxycycline (2 µg/mL) to induce AATF for 48 h. Gene expression was compared between cells 
overexpressing AATF and control cells using the Affymetrix GeneChip Rat Genome 230 2.0 
Array. Fold change represents AATF overexpression/control. (B) INS-1 832/13 cells were treated 
with or without doxycycline (2 µg/ml) to induce AATF for 48 h. Expression levels of AATF and 
TXNIP mRNA were measured by quantitative real-time PCR (Q-PCR) and standardized to actin 
(n=3; results are means ± SE).  
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TXNIP mRNA was downregulated in AATF overexpressing INS-1 832/13 cells (Figure 
2.1b). 
TXNIP expression is localized in pancreatic β-cells  
We primarily wanted to focus on understanding the components and mechanisms 
of ER stress-mediated apoptosis in β-cells as the UPR is cell-type specific. Therefore we 
wanted to confirm if TXNIP is preferentially expressed in pancreatic β-cells compared to 
other cell types in the pancreas. Immunostaining of mouse pancreas sections with anti-
TXNIP antibody together with anti-insulin or anti-glucagon antibody revealed that 
TXNIP was mainly found in islets where it co-localizes with insulin (upper panel, Figure 
2.2). TXNIP did not co-localize with glucagon suggesting that TXNIP has an important 
function in β-cells (lower panel, Figure 2.2). 
TXNIP expression is induced by ER stress in β-cells  
We next wanted to investigate whether TXNIP expression is induced by ER stress 
in β-cells. We measured mRNA expression levels of TXNIP in INS-1 832/13 cells 
treated with the pharmacological ER stress inducers, thapsigargin and tunicamycin. INS-
1 832/13 cells are commonly used in the ER stress field to study UPR signaling in β-cells 
due to their ability to respond to a variety of ER stress inducers, activate the UPR, and 
undergo cell death under severe ER stress. Thapsigargin is a strong ER stress inducer 
inhibiting the sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA) pump 
preventing its ability to pump calcium into the ER therefore depleting ER calcium stores. 
As a result, calcium dependant folding and processing enzymes cannot function properly 
decreasing the ER folding capacity. Tunicamycin inhibits N-acetylglucosamine-1-  
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Figure 2.2 TXNIP is expressed in pancreatic β-cells. Mouse pancreata were analyzed by 
immunohistochemistry with anti-TXNIP, anti-insulin, and anti-glucagon antibodies. Merged 
images show the co-localization of TXNIP and insulin (upper panel) or TXNIP and glucagon 
(lower panel) (n=3).   
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phosphate transferase (GPT) blocking the synthesis of N-linked glycoproteins. Most 
proteins in the ER are N-glycosylated and N-glycosylation is important for proper protein 
folding therefore tunicamycin causes ER stress. This ER stress is delayed compared to 
thapsigargin-induced ER stress due to the dependence upon protein biosynthesis. We 
found that TXNIP mRNA expression levels were increased by these chemical ER stress 
inducers (Figure 2.3a). In addition, TXNIP protein translation is also increased by these 
ER stress agents (Figure 2.3b). We further confirmed these findings by treating mouse 
and human primary islets with thapsigargin and tunicamycin. As predicted, TXNIP 
mRNA expression was increased in both mouse and human primary islets (Figure 2.3c). 
We also wanted to study if TXNIP expression is upregulated by pathological 
conditions known to cause ER stress in β-cells such as chronic high glucose and hIAPP. 
Chronic high glucose causes an overbearing amount of insulin biosynthesis leading to 
severe ER stress and a hyperactivated UPR favoring β-cell dysfunction and death54, 160. 
Human IAPP aggregation in islets is a common pathology of type 2 diabetes and has 
been shown to induce ER stress115-117.  Accordingly, TXNIP mRNA was increased by 
chronic high glucose and hIAPP in INS-1 832/13 cells (Figure 2.3d). Furthermore, we 
examined pancreatic islets isolated from the Akita mouse and also found TXNIP mRNA 
levels were elevated as compared to islets from control mice (Figure 2.3e). These 
heterozygous mutant Akita mice carry an Ins2C96Y mutation that disrupts proper disulfide 
bond formation within proinsulin-271. This mutated protein accumulates in the ER 
causing severe ER stress. Lastly, the saturated free fatty acid palmitate is another 
pathological ER inducer that can activate the UPR in a number of β-cell models95. In a  
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Figure 2.3 TXNIP expression is induced by ER stress. (A) INS-1 832/13 cells were treated 
with thapsigargin (TG, 0.25 µM) and tunicamycin (TM, 5 µg/mL) for the indicated number of 
hours. TXNIP mRNA levels were measured by quantitative real-time PCR (Q-PCR) and 
normalized to actin (n=3; values are mean ± SE). (B) INS-1 832/13 cells were treated with 
thapsigargin (TG, 1 µM, 8 h) and tunicamycin (TM, 5 µg/mL, 24 h). TXNIP and actin protein 
levels were measured by immunoblot (IB) (n=3). (C) Mouse and human primary islets were 
treated with thapsigargin (TG, 1 µM) and tunicamycin (TM, 5 µg/ml) for 6 h. Expression levels 
of TXNIP were measured by Q-PCR and normalized to actin (n=3; values are mean ± SE). (D) 
INS-1 832/13 cells with treated with glucose (16.7 mM) and human islet amyloid polypeptide 
(hIAPP, 5 µM) for the indicated number of hours. Expression levels of TXNIP were measured by 
Q-PCR and normalized with actin (n=3; values are mean ± SE). (E) Islets from C57BL/6 control 
mice and Akita mice were isolated. TXNIP mRNA levels were measured by Q-PCR and 
normalized to actin (n=3; values are mean ± SE). 
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previous study, palmitate was shown incapable of inducing TXNIP expression in isolated 
rat and mouse islets161, 162. To confirm these findings, we also examined the possibility 
that palmitate could induce TXNIP expression but failed to see an induction (data not 
shown).  
TXNIP expression is regulated by the IRE1α  and PERK-eIF2α  UPR pathways 
under ER stress 
 Collectively, we confirmed that a variety of pharmacological and pathological ER 
stimuli could lead to TXINP induction at both the mRNA and protein levels. Upon ER 
stress, the UPR master regulators, IRE1α, PERK, and ATF6α are activated13. For that 
reason, we next wanted to identify the UPR stress sensors involved in TXNIP induction.  
 During our research, we have found that TXNIP expression is regulated by the 
IRE1α and PERK arms of the UPR. TXNIP mRNA levels were modestly reduced in 
IRE1α siRNA knockdown INS-1 832/13 cells as compared to control under thapsigargin 
treatment (Figure 2.4a).  Similarly, TXNIP mRNA and protein levels were markedly 
attenuated in Ire1α-/- mouse embryonic fibroblasts (MEFs) as compared to wild type cells 
under ER stress (Figure 2.4b). TXNIP expression was also significantly reduced in both 
PERK siRNA knockdown INS-1 832/13 cells and Perk-/- MEFs (Figure 2.4c and 2.4d). 
No significant changes in TXNIP expression were observed in ATF6α siRNA 
knockdown INS-1 832/13 cells and ATF6α-/- MEFs (Figure 2.4e and 2.4f).  
Upon ER stress, activated PERK phosphorylates eIF2α attenuating global mRNA 
translation and transcriptionally influences gene expression32, 33. To determine if eIF2α  
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Figure 2.4 TXNIP expression is regulated under the IRE1α  and PERK-eIF2α  pathways of 
the UPR. (A) INS-1 832/13 cells were transfected with control scramble siRNA or IRE1α siRNA 
and then treated with thapsigargin (TG, 0.5 µM) for 6 h. TXNIP mRNA levels were measured by 
Q-PCR. Statistics were done by the unequal variance t-test (* p<0.05). (B) Wild-type (WT) and 
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Ire1α -/- (KO) MEFs were treated with thapsigargin (1.0 µM) for 3 h or untreated. Expression 
levels of TXNIP were measured by Q-PCR (left panel) and immunoblot (right panel). (C) INS-1 
832/13 cells were transfected with control scramble siRNA or PERK siRNA and then treated with 
thapsigargin (TG, 0.5 µM) for 6 h. TXNIP mRNA levels were measured by Q-PCR. (D) Wild-
type (WT) and Perk-/- MEFs were treated with thapsigargin (1.0 µM) for 3 h or untreated. 
Expression levels of TXNIP were measured by Q-PCR (left panel) and immunoblot (right panel). 
(E) INS-1 832/13 cells were transfected with control scramble siRNA or ATF6α siRNA and then 
treated with thapsigargin (TG, 0.5 µM) for 6 h. TXNIP mRNA levels were measured by Q-PCR. 
(F) Wild-type (WT) and Atf6α-/- MEFs were treated with thapsigargin (1.0 µM) for 3 h or 
untreated. TXNIP mRNA levels were measured by Q-PCR. (G) Wildtype eIF2αS/S (S/S) or 
mutant eIF2αA/A (A/A) MEFs were treated with thapsigargin (TG, 1.0 µm) for 3 h or untreated. 
TXNIP mRNA levels were measured by Q-PCR (left panel). TXNIP, phosphorylated eIF2α, 
CHOP, and actin protein levels were measured by immunoblot (right panel). Q-PCR results were 
normalized to actin and shown as means ± SE of three independent experiments. Representative 
immunoblots shown of three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  54  
phosphorylation has a role in TXNIP expression, we treated MEFS containing either a 
wild-type allele of eIF2α (eIF2αS/S) or an allele bearing the S51A mutation (eIF2αA/A) 
rendering eIF2α nonphosphorylatable with thapsigargin and measured TXNIP 
expression. We also measured expression of the PERK-eIF2α target CHOP as a positive 
control. Both TXNIP and CHOP expression levels were mitigated in eIF2αA/A MEFs 
(Figure 2.4g). Take together, theses results demonstrate that ER stress-mediated TXNIP 
expression is regulated by the IRE1α and PERK-eIF2α pathways. 
TXNIP transcription is regulated by ATF5 and ChREBP under ER stress 
 According to our results, the UPR significantly induces TXNIP mRNA levels and 
therefore we continued our studies investigating the underlying mechanisms involved. To 
test if TXNIP mRNA is induced at the transcriptional level, we transfected INS-1 832/13 
cells with luciferase reporter constructs containing 1.5 kb, 1.0 kb, or 0.5 kb of the TXNIP 
promoter. Cells were treated with or without thapsigargin 24 h post-transfection and 
assayed for luciferase activity. A renilla luciferase reporter vector was used as an internal 
control to normalize for transfection efficiency. The assay demonstrated that the 1.5 kb 
TXNIP luciferase reporter construct was most strongly activated by thapsigargin (Figure 
2.5a). 
We next investigated the influence of IRE1α and PERK on TXNIP transcription. 
To confirm that PERK-eIF2α signaling is involved in TXNIP transcription, we 
cotransfected the 1.5 kb TXNIP luciferase reporter construct with vectors expressing 
PERK or GADD34 in INS-1 832/13 cells followed by thapsigargin treatment. GADD34 
recruits phophotases to dephosphorylate eIF2α80-83. We observed that PERK stimulated  
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Figure 2.5 TXNIP transcription is regulated by ATF5 and ChREBP under ER stress in β-
cells. (A) INS-1 832/13 cells were transfected with TXNIP luciferase reporter constructs carrying 
0.5 kb, 1.0 kb, or 1.5 kb of the TXNIP promoter. After 24 h, cells were untreated (UT) or treated 
with thapsgargin (TG, 0.5 µM) for 6 h and then analyzed for luciferase activity. (B) INS-1 832/13 
cells were co-transfected with the 1.5 kb TXNIP luciferase reporter construct together with 
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control, PERK expression, or GADD34 expression vectors. After 24 h, cells were untreated (UT) 
or treated with thapsigargin (TG, 0.5 µM) for 6 h and then analyzed for luciferase activity. (C) 
INS-1 832/13 cells were co-transfected with the 1.5 kb TXNIP luciferase reporter construct and 
control scramble siRNA or ATF5 siRNA. After 24 h, cells were untreated (UT) or treated with 
thapsgargin (TG, 0.5 µM) and then analyzed for luciferase activity. (D) INS-1 832/13 cells were 
treated with or without thapsigargin (TG, 0.5 µM) for 6 h. The association of ATF5 on the 
TXNIP promoter was assessed by ChIP assays and quantified by Q-PCR. (E) INS-1 832/13 cells 
were transfected with control scramble siRNA or PERK siRNA. Then cells were treated with or 
without thapsigargin (TG, 0.5 µM) for 6 h. (left panel) Wild-type and Perk-/- MEFs were treated 
with or without thapsigargin (TG, 1.0 µM) for 3 h (right panel). ATF5 mRNA levels were 
measured by Q-PCR and normalized to actin. (F) INS-1 832/13 cells were co-transfected with the 
1.5 kb TXNIP luciferase reporter construct and control scramble siRNA or ChREBP siRNA. 
After 24 h, cells were untreated (UT) or treated with thapsgargin (TG, 0.5 µM) and then analyzed 
for luciferase activity. (G) INS-1 832/13 cells were treated with or without thapsigargin (TG, 0.5 
µM) for 6 h. The association of ChREBP and Mlx on the TXNIP promoter was assessed by ChIP 
assays and quantified by Q-PCR. (H) INS-1 832/13 cells were transfected with control scramble 
siRNA or PERK siRNA. Then cells were treated with or without thapsigargin (TG, 0.5 µM) for 6 
h (left panel). Wild-type and Perk-/- MEFs were treated with or without thapsigargin (TG, 1.0 
µM) for 3 h (right panel). ChREBP mRNA levels were measured by Q-PCR and normalized to 
actin. Results are means ± SE of three independent experiments.  
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TXNIP transcriptional activity whereas GADD34 suppressed it under ER stress (Figure 
2.5b). Co-transfection with IRE1α expression vector did not significantly stimulate the 
TXNIP reporter construct (data not shown). Therefore we concluded that the PERK-
eIF2α pathway has a major role in regulating TXNIP transcription under ER stress. 
Next we wanted to identify the transcription factors involved in regulating TXNIP 
expression under ER stress. The UPR transcription factors can bind to cis-acting response 
elements within UPR genes promoters163-165. These include ERSE (ER stress response 
element, 5'-CCAAT-N9-CCACG-3'), ERSE-II (ER stress response element II, 5’-
ATTGG-N1- CCACG-3’) and the UPRE (Unfolded Protein Response element, 5’-
TGACGTGG/A-3’). To reveal potential UPR transcription factors involved in TXNIP 
expression, we analyzed the TXNIP promoter for these consensus sequences yet we 
failed to locate such sequences.  
 Alternatively, we screened known transcription factors of the UPR including 
XBP-1, AATF, ATF3, ATF4, ATF5, and CHOP for their ability to regulate TXNIP 
expression. As expected, we determined XBP-1 was not involved in TXNIP transcription 
under ER stress in XBP-1 siRNA knockdown INS-1 832/13 cells and Xbp1-/- MEFs (data 
not shown). The remaining transcription factors are regulated under the PERK pathway 
and among them, ATF5 demonstrated a role in TXNIP transcription (Figure 2.5c). 
Knockdown of ATF3, ATF4 and CHOP by siRNA in INS-1 832/13 cells and Atf4-/- 
MEFs did not disrupt TXNIP expression under ER stress (data not shown). In addition 
regardless of our finding that AATF overexpression suppressed TXNIP expression, its 
knockdown did not augment TXNIP expression under ER stress (data not shown). 
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ATF5 is a member of the ATF/CREB family of b-ZIP transcription factors shown 
to be translationally upregulated under the PERK-eIF2α pathway in a similar fashion as 
ATF437. When we co-transfected INS-1 832/13 cells with the 1.5 kb TXNIP luciferase 
reporter construct with ATF5 siRNA followed by thapsigargin treatment, we measured a 
modest suppression of luciferase activity (Figure 2.5c) .We further investigated whether 
ATF5 binds to the TXNIP promoter. ChIP analysis using an ATF5 antibody 
demonstrated that ATF5 binding to the TXNIP promoter was enhanced by thapsigargin 
treatment (Figure 2.5d). We also confirmed that ATF5 expression is regulated by PERK. 
In PERK siRNA knockdown INS-1 832/13 cells and Perk -/- MEFs, ATF5 mRNA levels 
were attenuated under thapsigargin treatment (Figure 2.5e).  
We also screened known transcription factors of TXNIP focusing on those that 
may also be induced by ER stress. One candidate was forkhead box O1 transcription 
factor (FoxO1). FoxO1 has been shown to participate in TXNIP transcription under high 
glucose conditions in endothelial cells166. In addition FoxO1 activation may be induced 
by ER stress conditions such as palmitate through JNK phosphorylation167. We did detect 
modest changes in TXNIP mRNA levels in INS-1 832/13 cells transfected with FoxO1 
siRNA and FoxO1 expression vector (data not shown). However, no significant changes 
were observed in the activation of TXNIP luciferase reporter construct by FoxO1 
knockdown or overexpression and we failed to observe FoxO1 binding to the TXNIP 
promoter (data not shown).  
Another interesting candidate was ChREBP. TXNIP induction by glucose in β- 
cells is regulated by ChREBP binding to carbohydrate response elements (ChoREs) in the 
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TXNIP promoter143, 145, 168. Glucose is also known to induce ER stress and activate the 
UPR leading us to believe that perhaps the UPR can also regulate TXNIP transcription 
through ChREBP. To investigate the role of ChREBP in ER stress-induced TXNIP 
transcription, we transfected INS-1 832/13 cells with the TXNIP 1.5 kb luciferase 
reporter construct and ChREBP siRNA followed by thapsigargin treatment. Knockdown 
of ChREBP modestly suppressed luciferase activity under ER stress (Figure 2.5f). We 
confirmed that ChREBP binds to the TXNIP promoter by ChiP analysis using a ChREBP 
antibody (Figure 2.5g). Max-like protein (Mlx) has been shown to be a functional 
heteromeric partner of ChREBP in regulating the expression of ChREBP target genes 
raising the possibility that Mlx is also involved in TXNIP transcription. As expected, Mlx 
binding to the TXNIP promoter was also enhanced by thapsigargin treatment (Figure 
2.5g). We also observed that ChREBP expression was induced by ER stress and 
regulated by PERK. ChREBP mRNA levels were significantly decreased in PERK 
siRNA knockdown INS-1 832/13 cells and Perk -/- MEFs (Figure 2.5h).  Collectively, our 
results suggest that ATF5 and ChREBP regulate TXNIP transcription under ER stress in 
β-cells.  
TXNIP has a role in ER stress-mediated IL-1β production  
 It has been proposed that ER stress may induce inflammation but the mechanisms 
remain poorly characterized129. Remarkably we have found that tunicamycin and 
thapsigargin can upregulate the mRNA levels of the proinflammatory cytokine IL-1β in 
human islets (Figure 2.6a). In these experiments, as IL-1β is known to regulate  
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Figure 2.6 TXNIP mediates IL-1β production through the NLRP3 inflammasome under ER 
stress in β-cells. (A) Human islets were treated with thapsigargin (TG, 1 µM) and tunicamycin 
(TM, 5 µg/ml) for 6 h or untreated. IL-1β and IL-6 mRNA expression levels were measured by 
Q-PCR. (B) Human islets were pretreated with anakinra (IL1RA, 1 µg/mL) for 24 h followed by 
tunicamycin treatment (TM, 5 µg/ml) for 8 h. IL-1β and IL-6 mRNA expression levels were 
measured by Q-PCR. (C) INS-1 832/13 cells were stably transduced with pLenti-TO/shTXNIP, 
inducible lentivirus expressing shTXNIP. Cells were cultured with doxycycline (2 µg/ml) to 
induce shTXNIP or without doxycycline for 48 h, then challenged with thapsigargin (TG, 0.5 
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µM) for 6 h. IL-1β and IL-6 mRNA expression levels were measured by Q-PCR. (D) INS-1 
832/13 cells were transfected with control scramble siRNA or siRNA directed against NLRP3, 
then treated with or without thapsigargin (TG, 0.5 µM) for 6 h. IL-1β and IL-6 mRNA expression 
levels were measured by Q-PCR. Q-PCR results were normalized to actin and shown as means ± 
SE of three independent experiments.   
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expression of inflammatory factors, we measured IL-6 mRNA expression levels as a 
control. 
β-cells have been shown to secrete IL-1β and secreted IL-1β is capable of 
inducing its own expression through the binding of the highly expressed IL-1 receptor on 
the surface of β-cells140. Due to the low levels of IL-1β secretion and the capability of 
secreted IL-1β to associate with binding proteins, it is challenging to measure secreted 
IL-1β directly169. Instead we investigated if ER stress could stimulate the release of 
biologically active IL-1β by blocking IL-1 receptor activation with anakinra, the 
recombinant form of human IL-1 receptor antagonist. Human islets were preteated with 
anakinra for 24 h followed by tunicamycin treatment. Anakinra inhibited tunicamycin-
induced IL-1β and IL-6 mRNA expression (Figure 2.6b). These results indicate that 
active IL-1β is secreted and capable of autostimulation under ER stress.  
 Under oxidative stress, TXNIP participates in the activation of the NLRP3 
inflammasome leading to IL-1β production and secretion in β-cells142. Additionally, it 
has been recently reported that ER stress can activate the NLRP3 inflammasome leading 
to IL-1β secretion139. Furthermore, the NLRP3 inflammasome may be associated with the 
ER and upon activation relocalize to mitochondria-associated membranes (MAMs)136, 
contact sites in which the ER transfers signals to the mitochondria to initiate apoptosis137. 
Together these results raise the possibility that TXNIP may be involved in IL-1β 
production through the NLRP3 inflammasome under ER stress in β-cells.  
 Significant knockdown of TXNIP by siRNA could not be established and 
therefore we developed a doxycycline-inducible shRNA system that allowed efficient and 
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regulated knockdown of TXNIP in INS-1 832/13 cells. Using this system, we discovered 
that TXNIP downregulation lead to the attenuation of IL-1β and IL-6 mRNA expression 
levels under thapsigargin (Figure 2.6c).  
 To confirm the involvement of the NLRP3 inflammasome, we measured IL-1β 
and IL-6 expression in NLRP3 siRNA knockdown INS-1 832/13 cells treated with 
thapsigargin. NLRP3 directly binds to TXNIP and is a key component of the NLRP3 
inflammasome. We found that IL-1β and IL-6 expression was suppressed in cells 
deficient of NLRP3 (Figure 2.6d). Collectively, these results suggest that TXNIP has a 
role in ER-stress mediated IL-1β production through the NLRP3 inflammasome.  
TXNIP induces β-cell death partly through IL-1β  signaling under ER stress  
 We next wanted to explore the possibility that TXNIP is involved in ER stress 
mediated β-cell death. TXNIP has been shown to be a mediator of β-cell death under 
elevated glucose levels such as in diabetes159. Loss of TXNIP protected β-cells from 
apoptosis in several diabetic mouse models and isolated islets treated with high 
glucose159, 170 and therefore may also protect β-cells from ER stress. We challenged 
shRNA mediated TXNIP knockdown INS-1 832/13 cells with apoptotic thapsigargin 
conditions and observed reduced caspase-3 cleavage levels, a key component of the 
mitochondria apoptotic pathway (Figure 2.7a). We further confirmed these results by 
staining these cells with propidium iodide (PI) to identify cells that have lost cell 
membrane integrity and also with mitoprobe DilC1(5), which detects active 
mitochondrial membrane potentials. Accordingly, TXNIP suppression decreased the  
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Figure 2.7 TXNIP contributes to ER stress-mediated β-cell death through IL-1β signaling. 
(A) INS-1 832/13 cells were stably transduced with pLenti-TO/shTXNIP, inducible lentivirus 
expressing shTXNIP. Cells were cultured with or without doxycycline (Dox, 2 µg/ml) to induce 
shTXNIP 48 h, then challenged with thapsigargin (TG, 50 nM) and tunicamycin (TM, 5 µg/ml) 
for 24 h. Expression levels of TXNIP, caspase-3, and actin were measured by immunoblot (IB). 
Single and double asterisks indicate uncleaved and cleaved caspase-3, respectively. (B) INS-1 
832/13–TetR-shTXNIP cells were incubated with doxycycline (Dox, 2 µg/ml) for 48 h, then 
treated with thapsigargin (TG, 10 nM) for 24 h or untreated. Cells were stained with Mitoprobe 
DilC1(5) kit (Mitoprobe) and propidium iodide solution (PI) followed by flow cytometry 
analysis. (C) INS-1 832/13–TetR-shTXNIP cells were incubated with doxycycline (Dox, 2 
µg/ml) for 48 h and then treated with or without thapsigargin (TG, 50 nM) for 24 h. Viable cells 
were determined by measuring ATP levels using CellTiter-Glo luminescent cell viability assay. 
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Statistics were done by the Mann-Whitney test, * p<0.05. (D) Human primary islets (28 year old 
male, BMI 21, HbA1C 5.4) were treated with thapsigargin (TG, 1 µM) in the presence of BSA ( -
, 1 µg/ml) or anakinra ( +, 1 µg/ml) for 24 h. Caspase-3/7 activity was measured by Caspase-Glo 
3/7 assay. Results are means ± SE for three independent experiments. Statistics was done by two-
way ANOVA, * p<0.05. 
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amount of PI positive cells while increasing DilC1(5) stain intensities indicating 
protection of β-cells from ER stress-induced apoptosis (Figure 2.7b). Furthermore, 
TXNIP knockdown increased the number of viable cells in reflection of ATP intracellular 
levels (Figure 2.7c).  Therefore these observations confirm that TXNIP is an integral 
component of ER-stress mediated β-cell death.  
As demonstrated, TXNIP has a role in ER stress induced IL-1β production and 
autostimulation. IL-1β signaling has been shown to induce apoptosis in β-cells. To test if 
IL-1β mediates apoptosis under ER stress, human islets were treated with apoptotic 
thapsigargin in the presence of anakinra and as a result caspase-3 activity was reduced 
(Figure 2.7d). Collectively these findings suggest that TXNIP induced IL-1β production 
contributes to β-cell apoptosis under ER stress. 
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Discussion 
Through gene expression profiling of β-cells overexpressing AATF, we have 
uncovered a novel component of the UPR, thioredoxin interacting protein (TXNIP). 
TXNIP is transcriptionally upregulated by pharmacological and physiological ER stress 
inducers under the IRE1α and PERK-eIF2α arms of the UPR through transcription 
factors ATF5 and ChREBP in β-cells. Subsequently, TXNIP activates the NLRP3 
inflammasome leading to IL-1β secretion. IL-1β is capable of autostimulation through 
IL-1R1, eliciting a broad inflammatory response, and mediating β-cell death. Therefore, 
TXNIP is a mechanistic link between ER stress, inflammation, and apoptosis (Figure 
2.8).  
During our study we chose to focus on understanding the components and 
mechanisms involved in the UPR binary switch between life and death of the β-cell. 
Specifically, we chose to investigate TXNIP as a potential apoptotic component of the 
UPR in β-cells. Even though TXNIP is commonly described as a ubiquitously expressed 
gene, we observed that TXNIP is preferentially expressed in β-cells of pancreatic islets. 
We also found that a variety of ER stress stimuli can induce TXNIP expression in β-cell 
lines and isolated islets under IRE1α and PERK-eIF2α signaling pathways suggesting 
that TXNIP is an important component of the UPR in β-cells.  
As of note we confirmed that TXNIP could not be induced by palmitate in β-cells. 
Palmitate has been shown to induce ER stress leading to β-cell death95. However, past 
studies demonstrate that TXNIP is actually repressed by palmitate in β-cells161. More 
recently a group discovered that palmitate affects TXNIP transcription by inhibiting  
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Figure 2.8 TXNIP induces ER stress-mediated β-cell inflammation and apoptosis. ER stress 
upregulates TXNIP expression under PERK-eIF2α and IRE1α signaling pathways and 
transcriptionally through ChREBP and ATF5. In turn, TXNIP activates the NLRP3 
inflammasome leading to the processing and secretion of active IL-1β. IL-1β is capable of 
autostimulation through IL-1R1 inducing its own transcription. IL-1β also recruits macrophages 
to islets leading to a broad inflammatory response. In addition, TXNIP contributes to ER stress-
induced β-cell death partly through IL-1β signaling. 
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ChREBP nuclear translocation possibly through AMP-activated protein kinase 
(AMPK)162. AMPK is an energy sensor and has several functions including regulating 
fatty acid metabolism. AMPK activity is enhanced by palmitate but reduced by glucose. 
Knockdown of AMPK partially increased TXNIP expression levels under glucose and 
palmitate conditions.  AMPK may possibly modulate ChREBP activity by 
phosphorylation. 
We also investigated the possible mechanisms of ER stress-mediated TXNIP 
transcription and revealed the involvement of transcription factors ATF5 and ChREBP. 
ATF5 has been demonstrated to be translationally upregulated under the PERK-eIF2α 
pathway37. Its target genes under ER stress have not been identified but a potential 
candidate is CHOP171 and here we demonstrate TXNIP. Hence, ATF5 may play a role in 
inducing apoptotic genes in β-cells under severe ER stress. Further studies are needed to 
study the effect of overexpressing ATF5 and subsequently the genes it modulates in β-
cells.  
ChREBP is a basic helix-loop-helix leucine zipper transcription factor that 
partners with Mlx to bind to ChoRE motifs in the promoters of glucose-responsive 
genes172, 173.  ChREBP has been well characterized for its ability to regulate genes 
involved in lipogenesis and glycolysis in response to glucose in liver174. Recently it has 
also been shown that ChREBP can regulate glucose-sensitive genes including TXNIP in 
β-cells promoting dysfunction and apoptosis143, 175, 176. Here we reveal that ChREBP is a 
novel transcription factor of the UPR.  Under ER stress, ChREBP mRNA levels increase 
and is regulated under the PERK pathway; however, the exact mechanisms need to be 
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elucidated. A possible mechanism for ChREBP activation may involve ER calcium 
release. A new report has found that ChREBP binds to a binding protein sorcin that 
senses cytosolic calcium levels177. Upon an increase in calcium levels, sorcin releases 
ChREBP to allow for its translocation into the nucleus to regulate transcription. This 
mechanism should be explored in the context of ER stress as ER stress has been proposed 
to trigger ER calcium release. In addition like ATF5, it would be interesting to analyze 
gene targets of ChREBP that may reveal novel components of the UPR.   
On the other hand, we could not confirm a role for FoxO1 in TXNIP transcription. 
FoxO1 belongs to the family of forkhead transcription factors. The TXNIP promoter 
contains a conserved FoxO consensus site.  A study has demonstrated that FoxO1 can 
induce TXNIP transcription in neurons178 and in another study FoxO1 upregulates 
TXNIP transcription under high glucose in human aortic epithelial cells166. In addition 
FoxO1 has been shown to be activated by JNK mediating ER stress and fatty acid-
induced β-cell death in part through CHOP induction167. Therefore FoxO1 was an 
attractive candidate potentially involved in TXNIP transcription under ER stress in β-
cells. However, even though we could see some attenuation of TXNIP expression upon 
FoxO1 knockdown, we did not observe FoxO1 binding to the TXNIP promoter or FoxO1 
activation of the TXNIP luciferase reporter construct under ER stress. A possible 
explanation may be related to the recent finding that XBP-1 can bind to FoxO1 
promoting its degradation by the proteosome179. Moreover, the UPR can also activate 
Akt48, 180-182, which is an established inhibitor of FoxO1 nuclear translocation.  
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We also could not confirm a role for AATF in TXNIP transcriptional regulation. 
We originally identified TXNIP as a gene downregulated by AATF overexpression. 
However, upon AATF knockdown, we did not detect modulation of TXNIP expression. 
There are several possible explanations including overexpressed AATF acting as a 
negative inhibitor of TXNIP positive regulating transcription factors. Regardless, we 
conclude that AATF is not a major regulator of TXNIP transcription.  
Despite our findings, the detailed mechanisms of ER stress-induced TXNIP 
expression remain incomplete.  TXNIP transcription regulation under ER stress is most 
likely governed by additional unidentified transcription factors. A yeast one-hybrid 
screen in the future would reveal other key players involved. Furthermore, we revealed 
that IRE1α is not involved in the transcriptional regulation of TXNIP, which suggests 
that other mechanism are involved in TXNIP expression. Indeed Feroz Papa and his 
colleagues discovered that IRE1α upregulates TXNIP mRNA levels by degrading its 
destabilizing micro-RNA, miR-17 (unpublished). They have also revealed that TXNIP is 
translationally regulated by unknown mechanisms. Combining multiple means of 
regulation may ensure cells to efficiently increase TXNIP expression under ER stress 
conditions.  
 Accumulating evidence suggests that ER stress is a mediator of β-cell dysfunction 
and death during the development of diabetes8-10. β-cells experience ER stress on a 
regular basis as they increase insulin biosynthesis in response to fluctuations in blood 
glucose levels. As a consequence, β-cells are armed with a specialized ER and UPR to 
handle these physiological demands.  Ironically when ER stress is unresolvable, this very 
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UPR system can switch over to pathological outputs including disruption in proinsulin 
folding and production, reduction in insulin secretion, oxidative stress, apoptosis, and 
inflammation. The molecular mechanisms underlying these consequences remain to be 
clarified. In particular, little progress has been made in understanding how ER stress can 
invoke inflammation. In this study, we have demonstrated that TXNIP is a key link 
between ER stress and inflammation.  
 Inflammation is a pathological component in type 1 diabetes and more recently it 
has been suggested to play a role in type 2 diabetes140, 141. Type 1 diabetes develops as a 
result of an autoimmune destruction of β-cells mediated by proinflammatory cytokines 
such as IL-1β. Interestingly, overnutrition associated with type 2 diabetes development 
can induce β-cells to secrete IL-1β183. Consequently, macrophages are recruited to islets 
and increase IL-1β levels184. Meanwhile, IL-1β can bind to IL-1R1 receptors expressed 
on the surface of β-cells triggering autostimulation leading to a vicious cycle of β-cell 
destruction. Type 2 diabetic patients who suffer from this mechanism of β-cell loss most 
likely have lower levels of the endogenous antagonist of IL-1 signaling, IL-1RA185. 
Accordingly, these patients respond quite well to anakinra, the recombinant form of IL-
RA or neutralizing anti-IL-1β antibodies improving glycemic control and insulin 
production while reducing inflammatory markers150, 186. 
 The mechanisms of IL-1β production in β-cells have recently been identified. 
Under high glucose, ROS production causes thioredoxin to release TXNIP and in turn 
binds to and activates the NLRP3 inflammasome142. The NLRP3 inflammasome 
processes IL-1β leading to secretion of active IL-1β. Here we demonstrate that TXNIP 
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regulates IL-1β production through the NLRP3 inflammasome under ER stress.  
Therefore excessive nutrients such as high glucose induce ER stress and activate the UPR 
leading to β-cell secretion of IL-1β through TXNIP.  As ROS and potassium efflux are 
required for inflammasome activation in islets, studies should confirm their requirement 
specifically in β-cells.  
Contradictory to our results, Menu et al. concluded that the classical UPR is not 
involved in activating the inflammasome in macrophages139. However, they did observe 
NLRP3 inflammasome activation and IL-1β secretion triggered by ER stress. 
Remarkably, the same group also demonstrated that upon activation, the NLRP3 
inflammasome travels from the ER to mitochondria ER associated membranes 
(MAMs)136.  At these contact sites, the ER transfers metabolites, lipids and calcium to the 
mitochondria to initiate signaling pathways including apoptosis137.  Calcium uptake by 
the mitochondria can also increase mitochondrial ROS production124, which may 
influence NLRP3 inflammasome activation. It would be interesting to study the 
localization of the NLRP3 inflammasome in the β-cell under ER stress.  
 We also conclude that secreted IL-1β is capable of autostimulation through its 
receptor, IL-1R1 on β-cells under ER stress. Presumably as a consequence, IL-1β induces 
expression of itself and chemokines through activation of NF-κB. Studies have 
demonstrated that NF-κB also regulates the expression of inducible nitric oxide synthase 
(iNOS) leading to nitric oxide (NO) production187. Even though controversial, NO 
suppresses SERCA2B expression contributing to the depletion of ER calcium levels and 
consequently ER stress105. In line with these observations, markers of the UPR including 
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spliced XBP-1, phosphorylated PERK and eIF2α, ATF4, and CHOP are detected in β-
cell lines treated with IL-1β. Interestingly, BiP is actually downregulated by IL-1β 
therefore hampering ER folding capacity188. It has also been recently reported that NF-κB 
can directly bind to the CHOP promoter and upregulate its transcription189. CHOP has 
been implicated to play a role in ER stress mediated β-cell death. CHOP depletion 
partially protects β-cells from IL-1β108. IL-1β is also capable of activating JNK190. JNK is 
a mitogen-activated protein kinase (MAPK) that mediates β-cell cell death. Inhibiting 
JNK activation protects β-cells from IL-lβ191, 192. The JNK pathway also has a role in 
regulating CHOP transcription through AP-1 under cytokine treatment64. Collectively, 
IL-1β signaling is complex and needs to be studied carefully in the context of ER stress 
in β-cells. It may be challenging to determine if ER stress-mediated IL-1β 
autostimulation induces NF-κB and JNK activation as ER stress itself can induce the 
activation of these molecules. Nevertheless, we have found that IL-1β signaling may 
partially be involved in ER stress induced β-cell death.  
 Besides autostimulation, the UPR and TXNIP may influence IL-1β transcription 
directly. Our data demonstrates increased IL-1β mRNA levels under ER stress conditions 
and these levels are reduced by PERK and TXNIP knockdown or GADD34 
overexpression. One possible mechanism involves NF-κB. NF-κB is a known 
transcriptional regulator of IL-1β193. The PERK-eIF2α pathway reduces translation of the 
IκB promoting NF-κB activation and perhaps leading to IL-1β transcription133, 134. 
Another possible mechanism includes TXNIP. TXNIP has been shown to localize within 
the nucleus possibly by importin-α and TXNIP overexpression modulates β-cell 
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transcription possibly as a transcriptional repressor194-196. Thus TXNIP may influence the 
activities of IL-1β transcription factors or histone modifiers. These possible mechanisms 
should be explored.     
 We also explored the possibility that TXNIP mediates β-cell death under ER 
stress. Studies have demonstrated that glucose-mediated TXNIP expression has an 
apoptotic role in β-cells159. Overexpressing TXNIP in β-cell lines induces apoptosis.  
Isolated islets from TXNIP mutant mice are protected from glucose-induced cell death. 
TXNIP mutant or β-cell specific knockout mice crossed with diabetic mouse models 
demonstrated increased β-cell mass and reduced β-cell apoptosis170. Likewise, we have 
found that TXNIP knockdown protected β-cell lines from ER stress-mediated cell death. 
Furthermore, Feroz Papa and his colleagues revealed that crossing TXNIP knockout mice 
with the heterozygous Akita mice protected these mice from β-cell apoptosis and ER 
stress induced diabetes (unpublished). Clearly these results confirm that TXNIP has a 
role in ER stress mediated β-cell death.  On the contrary, Anath Shalev’s group 
demonstrated that isolated islets from β-cell specific TXNIP knockout mice were not 
protected from ER stress induced-apoptosis161. This discrepancy is most likely due to 
experimental differences in ER stress induction. Moreover, the UPR is composed of other 
apoptotic components that are likely involved in β-cell apoptosis. Therefore, knocking 
down or knocking out TXNIP will partially protect β-cells from ER stress.  
 Even though we show a partial contribution of IL-1β signaling, the mechanisms 
of TXNIP induced β-cell death under ER stress remain elusive. TXNIP directly binds to 
the active site of thioredoxin inhibiting its protein reducing and ROS scavenging 
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abilities147-149. Hence TXNIP may increase intracellular ROS levels triggering β-cell 
apoptosis. Thioredoxin also binds and inhibits a variety of apoptotic factors such as ASK-
1197. It has been proposed that under oxidative stress TXNIP shuttles from the nucleus to 
the mitochondria to inhibit the mitochondria resident thioredoxin 2 thereby promoting 
ASK-1 activation and β-cell apoptosis194. This mechanism may be possible in our studies 
as ER stress has been shown to induce oxidative stress.  ER stress also activates 
cytoplasmic ASK-1 through IRE1α-TRAF256. Thus TXNIP may contribute to ASK-1 
activation by this mechanism.  
 TXNIP also has a role in negatively regulating glucose stimulated insulin 
secretion (GSIS). Mutant or TXNIP knockout mice demonstrated enhanced GSIS198, 199. 
Silencing TXNIP in INS-1 and MIN6 cells demonstrated enhanced GSIS whereas 
overexpressiong TXNIP suppressed GSIS157, 158. A potential mechanism may involve 
TXNIP suppression of mitochondria ATP levels by upregulating mitochondria 
uncoupling protein 1 (UCP-1) transcription through recruitment of PPARγ co-activator-
1α (PGC-1α) to the UCP-1 promoter158.  In addition, TXNIP may bind and inhibit 
Mybbp1a, a negative regulator of PGC-1α thus promoting UCP-1 transcription. UCP-1 is 
known to suppress mitochondria ATP levels and GSIS. Hence TXNIP may also be a link 
between the UPR and impaired GSIS.  
 Accumulating evidence indicate that TXNIP has a role in the pathogenesis of type 
2 diabetes. A recent study found that TXNIP polymorphisms were associated with type 2 
diabetes and high blood pressure200. Carriers of one of these polymorphisms exhibited 
higher levels of TXNIP expression in smooth muscle cells. Lymphocytes from type 2 
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diabetic patients and patients with impaired glucose tolerance demonstrated higher 
TXNIP expression levels201.  Parikh et al. found that TXNIP expression in skeletal 
muscle was higher in prediabetic and diabetic patients202. They further discovered that 
TXNIP is a negative regulator of blood glucose uptake by fat and muscle cells. 
Accordingly, TXNIP deficient mice exhibit increased insulin sensitivity153, 199.  The 
mechanisms may involve TXNIP downregulation of insulin signaling components such 
as Akt phosphorylation and insulin receptor substrate 1 (IRS-1)158. Thus it would be 
important to study TXNIP regulation and function under ER stress in muscle and fat 
cells.  
Furthermore, TXNIP expression is induced by glucose in fat and muscle cells like 
β-cells and in all of these cell types, insulin suppresses TXNIP expression202, 203. 
Therefore TXNIP behaves as a homeostatic switch controlling glucose uptake by 
peripheral tissues and insulin secretion by β-cells. A balance between glucose and insulin 
levels ensures that TXNIP expression is properly regulated. However, when β-cells can 
no longer compensate for insulin resistance, glucose and insulin levels are dysregulated 
favoring TXNIP overexpression exacerbating insulin resistance and β-cell failure leading 
to type 2 diabetes.  
 Collectively, these results along with ours establish TXNIP as a potential target in 
diabetes therapy. Diabetes ensues only when the β-cell fails. TXNIP clearly has a role in 
β-cell dysfunction and death during diabetes development. Understanding the 
mechanisms involved in TXNIP regulation under glucose and insulin conditions may 
uncover strategies to modulate its expression or activity. Moreover, exploring how 
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TXNIP elicits its harmful affects will also shed some light on therapeutic interventions 
Here we demonstrate that the UPR through the PERK-eIF2α and IRE1α pathways 
regulate TXNIP expression. The PERK-eIF2α pathway regulates TXNIP at the 
transcriptional level through ChREBP and ATF5.  Additionally, we discovered that 
TXNIP has apoptotic and inflammatory roles under ER stress through the NLPR3 
inflammasome production of IL-1β. Targeting TXNIP and components of these pathways 
are candidates for developing diabetes treatment. 
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CHAPTER III 
PERSPECTIVES 
 
 Diabetes mellitus is a major health problem affecting 366 million people 
worldwide in 2011 and will rise to 552 million by 2030204. About 90-95% of diabetes 
cases are type 2 diabetes. Type 2 diabetes is a result of genetic and environmental factors 
that lead to insulin resistance and β-cell failure causing hyperglycemia. Hyperglycemia 
gives rise to several life threatening long term complications including heart attacks, 
strokes, diabetic retinopathy, kidney failure, and amputations. Therefore it is clear the 
importance of understanding the pathogenesis of diabetes to develop novel therapies.  
 Metabolic overload often due to obesity impairs insulin action in the skeletal 
muscle, adipose tissue, and liver4, 205. As a result glucose uptake is reduced in the muscle 
and adipose tissues. Adipose tissues also release excess levels of free fatty acids and 
other factors that promote insulin resistance in the muscle and liver. Reduced insulin 
sensitivity in the liver leads to increased glucose production. As a result, insulin 
resistance leads to higher blood glucose levels. Pancreatic β-cells compensate by 
increasing insulin secretion. However, for a subset of genetically predisposed individuals, 
β-cells fail to compensate due to dysfunction and loss. Consequently, type 2 diabetes 
develops with chronic high blood glucose levels along with increased circulating free 
fatty acids.  These elevated levels of nutrients exacerbate β-cell failure by inducing 
oxidative stress, inflammation, and ER stress8, 9, 141.   
  80  
The ER is the major site for proinsulin folding and processing in the β-cell. 
During physiological changes in glucose levels, the increased proinsulin ER load 
overwhelms the ER folding capacity causing an accumulation of unfolded proteins54. As 
β-cells often experience ER stress, they have an elaborate ER and UPR to activate 
adaptive mechanisms that mitigate ER stress, restore ER homeostasis, and promote cell 
survival. However, upon conditions associated with type 2 diabetes, ER stress is severe 
and the UPR becomes hyperactivated causing β-cell dysfunction, oxidative stress, 
inflammation, and death.  Thus the UPR switches from physiological to pathological 
outcomes10, 45. Understanding the mechanisms and components involved in this switch 
will shed light on β-cell failure and potential targets for drug development.  
 In this study, we began our focus on identifying the survival and death 
components of the UPR in the β-cell. During a DNA microarray analysis, we have 
selected TXNIP as an interesting candidate to study. Accumulating evidence indicates 
that TXNIP has a central role in maintaining glucose homeostasis. At physiological 
conditions, TXNIP expression is reciprocally regulated by insulin and glucose and 
functions as a break for insulin secretion in β-cells157, 158. However as insulin resistance 
ensues, higher glucose levels lead to pathological levels of TXNIP expression inhibiting 
GSIS and promoting β-cell apoptosis159. Hence we hypothesized that TXNIP may be 
involved in ER stress mediated β-cell apoptosis. 
 Interestingly during our research, we discovered that TXNIP has a role in β-cell 
inflammation and apoptosis under ER stress. We demonstrated that TXNIP is mainly 
expressed in β-cells of the pancreas and is induced by both pharmacological and 
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pathological ER stress inducers under the IRE1α and PERK-eIF2α arms of the UPR. At 
the transcriptional level, TXNIP is regulated by ATF5 and ChREBP transcription factors. 
As we explored possible functions of TXNIP, we have found that TXNIP has a role in 
ER stress mediated IL-1β production and autostimulation. Furthermore, we confirmed 
that TXNIP does indeed contribute to ER stress-induced β-cell apoptosis partially 
through IL-1β signaling.    
 TXNIP not only has a role in β-cell failure as we and others have demonstrated, 
but TXNIP also reduces glucose uptake in peripheral tissues202 and increases hepatic 
glucose production206. Therefore TXNIP is an aggravator of type 2 diabetes. Notably, 
TXNIP is a potential molecular link between ER stress, oxidative stress, and 
inflammation (Figure 3.1a). Such a model implicates that as blood glucose levels increase 
due to insulin resistance, ER stress becomes severe in the β-cell and induces pathological 
factors such as TXNIP. TXNIP in turn can inhibit thioredoxin147-149 promoting activation 
of apoptotic pathways and ROS production and/or activate the NLRP3 inflammasome 
leading to IL-1β secretion, autostimulation, and inflammation142. In addition, studies 
demonstrate that increased TXNIP expression also suppresses GSIS157, 158, thus this 
phenomenon is probable under ER stress. As a result, the functional β-cell mass 
decreases which further increases blood glucose levels and TXNIP expression levels in β-
cells as well as in peripheral tissues creating a downward spiral to overt type 2 diabetes 
(Figure 3.1b). Collectively, these studies select TXNIP as an attractive target for type 2 
diabetes therapies. 
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Figure 3.1 TXNIP expression contributes to type 2 diabetes. (A) TXNIP is a link between ER 
stress, oxidative stress, and inflammation in β-cells. These different pathological outputs can feed 
into each other causing a vicious cycle leading to β-cell failure. (B) During insulin resistance, as 
blood glucose levels increase causing ER stress in β-cells, TXNIP expression is induced leading 
to decreased GSIS and increased levels of ROS, IL-1β and apoptosis. High glucose also induces 
TXNIP expression in muscle and fat cells leading to impaired glucose uptake. Taken together, 
TXNIP expression worsens insulin resistance and β-cell failure leading to overt type 2 diabetes.  
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 In particular, it is becoming more apparent that early therapeutic intervention 
alleviating β-cell function and promoting survival could potentially prevent the transition 
to diabetes207.  Currently 79 million Americans have prediabetes1 characterized by 
impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) mostly due to 
insulin resistance. As the functional β-cell mass declines, about 40-50% of IGT patients 
will progress to type 2 diabetes. Once type 2 diabetes develops, β-cells continue to 
deteriorate even with therapeutic interventions208 and severe complications are likely to 
develop. Therefore early intervention for high-risk prediabetic individuals could prevent 
or delay the progression to type 2 diabetes. Even though diet and exercise reduces 
conversion to diabetes by 50-60%, it is difficult to establish and maintain207. A more 
effective strategy is with use of pharmacological therapies that especially focus on 
preserving functional β-cell mass.  
As TXNIP is a mediator of β-cell failure, understanding the mechanisms of 
TXNIP expression, activity, and function will shed light on strategies to prevent diabetes. 
In this work we present significant novel findings that TXNIP is a component of the 
UPR, mediates IL-1β production and autostimulation, and has a role in β-cell death under 
ER stress. These findings among others have begun to reveal different components of ER 
stress, oxidative stress, and inflammation that could be therapeutic targets against β-cell 
dysfunction and death. 
One strategy is to target ER chaperone capacity with chemical chaperones such as 
4-phenylbutryic acid (PBA) and tauroursodeoxycholic acid (TUDCA). During ER stress, 
the ER folding capacity is overwhelmed by the ER protein load. Chemical chaperones 
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could potentially improve the ER folding capacity therefore alleviating ER stress. Use of 
these chemical chaperones demonstrated improvement of hyperglycemia and insulin 
resistance in ob/ob mice209. TUDCA demonstrated improvement of insulin secretion in 
isolated islets210. More recently, in vivo administration of PBA and TUDCA in 48 h high 
glucose treated rats reduced β-cell ER stress and restored β-cell function211. However, 
such compounds have yet to be shown effective in humans and lack specificity 
potentially affecting a wide range of cells.  Furthermore, these chaperones are effective at 
high dosages, which may be toxic in humans.   
A more specific drug may be BiP inducer X (BIX), which induces transcription of 
the ER resident chaperone BiP. Studies show that BIX is capable of protecting neurons 
from ER stress mediated-cell death212, 213. In the β-cell, BiP overexpression improved 
proinsulin levels and GSIS under high glucose conditions214 and has a protective effect 
against free fatty acids101. Taken together, it would be interesting to study the effects of 
BIX and in general other means of inducing chaperones on β-cell failure in vitro and in 
vivo.  
Another strategy is the use of antioxidants. Under high glucose and fatty acid 
conditions, excessive amounts of ROS are produced contributing to β-cell failure. Several 
mechanisms are responsible for ROS production including oxidative protein folding in 
the ER119 and calcium leakage from the ER to the mitochondria increasing mitochondrial 
ROS production124.  TXNIP binding to the antioxidant thioredoxin also results in ROS 
production215. ROS inhibits ER and β-cell function, and leads to β-cell apoptosis. In 
addition, β-cells lack antioxidants and are especially vulnerable to ROS122. 
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Administration of antioxidants such as N-acetyl cysteine216, 217 and probucol218, 219 have 
shown improvement of diabetic symptoms in vitro and in vivo.  Interestingly, probucol 
reduces oxidative stress in islets in part by increasing thioredoxin expression while 
decreasing TXNIP expression. However, evidence for antioxidants usefulness in 
improving β-cell failure in humans is lacking.  
An additional strategy may involve maintaining an oxidized ER. Under healthy 
conditions, the ER houses an oxidized environment to promote disulfide bond formation 
during protein folding119, 220. Stimuli such as high glucose and hIAPP reduce the ER as a 
mechanism to cause ER stress and consequently apoptosis. Our lab has developed a 
method to monitor ER redox states in the β-cell line, INS-1 832/13. These cells express a 
modified redox-sensitive green fluorescent protein (GFP) named MERO-GFP 
(Mammalian Endoplasmic reticulum-localized RedOx-sensitive GFP)221.  Upon ER 
reduction, a change of fluorescence of MERO-GFP as a result of disulfide bond 
disruption can be quantified. Using this redox monitoring system, we screened 
pharmacologically active compounds that can maintain an oxidizing ER under ER stress 
and discovered two compounds, apomorphine and pioglitazone (unpublished). We were 
able to confirm the ability of these drugs to maintain an oxidized ER under ER stress and 
also to protect cells from ER stress-induced apoptosis. Apomorphine is a dopamine 
agonist used to treat Parkinson’s disease222. Interestingly, pioglitazone is a drug used to 
treat type 2 diabetes that improves insulin sensitivity by activating peroxisome 
proliferator-activated receptor γ (PPARγ) and also preserves β-cell function223, 224. A 
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study demonstrated a 72% reduction in conversion from IGT to type 2 diabetes using 
pioglitazone and therefore is a recommended drug for diabetes prevention225.   
These drugs discussed thus far are capable of relieving ER stress, but more direct 
targets of the UPR signaling network would be ideal for drug development. Targeting 
upstream components such as the UPR master regulators, IRE1α, PERK, and ATF6α and 
also eIF2α phosphorylation should be considered with caution.  These components 
switch from physiological to pathological outputs. As β-cells require these upstream UPR 
components for adaptation and survival, inhibiting them would reduce β-cell defenses 
against ER stress. Likewise, activating these pathways may cause a switch to β-cell 
failure. Therefore techniques that focus on activating UPR homeostatic survival 
components and inhibiting components involved in dysfunction and death are more 
promising therapeutic strategies.  
One proposed method is to inhibit the kinase activity of IRE1α. Under 
physiological ER stress conditions, IRE1α dimerizes, autophosphorylates, and splices 
XBP-1 mRNA to produce mature XBP-1 transcription factor. XBP-1 regulates 
homeostatic UPR genes. However under severe ER stress, IRE1α becomes 
hyperactivated triggering decay of ER associated mRNAs including preproinsulin and 
activating apoptotic pathways. During such conditions, it is hypothesized that IRE1α 
luminal domains undergo higher order oligerimization leading to increased 
phosphorylation, RNase activity, and promiscuous mRNA degradation28.  Kinase activity 
is required for this harmful mRNA decay. Thus identifying kinase inhibitors that prevent 
IRE1α autophosphorylation and favor activation of IRE1α RNase domains that promote 
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XBP-1 mRNA splicing without destructive mRNA decay are promising tools to alleviate 
β-cell failure.  Such compounds such as APY29 show promise in uncoupling the different 
RNase activities of IRE1α. 
Another method is to inhibit the RNase activity of IRE1α altogether. In patients 
with prediabetes, glucose levels may be high enough to hyperactivate IRE1α leading to 
ER mRNA decay. Even though XBP-1 is still being processed, its homeostatic activity is 
negligible and in fact it has been reported that extensive XBP-1 splicing may trigger 
apoptosis. Therefore inhibiting endoribonucleolytic activity of IRE1α should promote β-
cell function and survival. Feroz Papa and colleagues took this approach with the IRE1α 
endoribonuclease inhibitor STF083010226. Their group discovered that IRE1α RNase 
activity promotes TXNIP mRNA stability by degrading the miRNA, miR-17. Using 
STF083010 to prevent this pathway, TXNIP mRNA is degraded preventing IL-1β 
production (unpublished). Further studies on the effect of these kinase and RNase 
inhibitors on β-cell function and survival should be conducted in vivo.  
Further downstream the UPR stress sensors, regulators of TXNIP transcription 
may be good targets. One approach in this regard is targeting ChREBP. Under basal 
glucose levels, sorcin binds to ChREBP restricting it to the cytoplasm177. Upon high 
glucose, calcium influx is sensed by sorcin triggering ChREBP release and subsequently 
translocation into the nucleus. Consequently, ChREBP upregulates pathological genes 
such as TXNIP and downregulates genes involved in β-cell function143, 175.  Therefore 
finding drugs that inhibit ChREBP activity could potentially be used to prevent β-cell 
failure. Interestingly, a recent study demonstrated that the calcium channel blocker, 
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verapamil, reduces TXNIP expression by preventing ChREBP nuclear translocation 
perhaps through increased ChREBP phosphorylation and/or inhibiting calcineurin 
signaling227. The possibility of sorcin involved in ChREBP nuclear exclusion by 
verapamil should also be investigated. Regardless, verapamil was able to enhance β-cell 
function and survival improving diabetic symptoms in diabetic mice. Because verapamil 
is already an approved drug, it is an especially strong candidate to prevent β-cell failure 
in humans.  
A new group of diabetic drugs, the GLP-1 analogues have been shown to rescue 
β-cell failure partly through reducing ER stress and TXNIP expression228. GLP-1 is an 
incretin released from the large intestines after a meal that stimulates insulin secretion 
and biosynthesis, reduces glucagon secretion, delays gastric emptying, and promotes 
satiety. One group of GLP-1 analogues are the GLP-1 receptor agonists including the 
approved drugs liraglutide and exenatide. Exenatide is the synthetic form of exendin-4. 
Exendin-4 has been shown to reduce expression of ER stress, oxidative stress, and 
inflammatory markers of β-cells in vitro and in vivo229-231. In addition exendin-4 also 
reduces TXNIP expression levels through cyclic AMP (cAMP) signaling leading to 
TXNIP proteasomal degradation232, 233, which provides an explanation for the drug’s β-
cell protective effects. Because GLP-1 analogues promote β-cell function and survival, 
cause weight loss, lower blood pressure, have little side effects and are long lasting, they 
are great candidates to prevent type 2 diabetes207.  
As mentioned previously, pioglitazone was discovered for its ability to maintain 
an oxidized ER and prevent β-cell death under ER stress. Pioglitazone may also target 
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TXNIP expression through PPARγ. PPARγ, a member of the nuclear receptor 
superfamily, regulates several biological processes including adipogenesis and glucose 
metabolism. PPARγ has been shown to negatively regulate TXNIP transcription in 
proximal tubule kidney cells and in adipose tissues perhaps by directly binding to 
peroxisome proliferator response elements (PPREs) in the TXNIP promoter234-236. Under 
high glucose conditions, PPARγ expression is suppressed and TXNIP expression is 
induced. But treatment with pioglitazone or the similar PPARγ agonist rosiglitazone 
reduced TXNIP expression in kidney and fat cells. Similarly, we have found that 
pioglitazone was able to suppress ER stress-induced TXNIP expression in β-cells (data 
not shown). In addition, PPARγ has anti-inflammatory roles including decreasing the 
expression of cytokines perhaps through TXNIP236, 237. Collectively, these data further 
explain the beneficial effects of pioglitazone in preventing diabetes.  
TXNIP also activates the NLRP3 inflammasome leading to the production of the 
proinflammatory cytokine IL-1β142. A number of studies propose that IL-1β signaling 
and inflammation contribute to the pathogenesis of type 2 diabetes140, 141. Several markers 
of inflammation are found in diabetic patients such as increased IL-1β serum levels and 
increased islet-localized macrophages. Inflammation in type 2 diabetic patients are most 
likely due to decreased expression of the endogenous IL-1β antagonist, IL-1RA. Clinical 
trials with anakinra, the recombinant form of IL-1RA, and IL-1β specific antibodies were 
able to improve glycemia and β-cell function especially for those individuals that carry 
IL-1RA variants150.  Because these therapeutic strategies are safe and long lasting, they 
may be ideal candidates to treat prediabetic patients.  
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Modulating NLRP3 inflammasome activity is also an approach to examine. A 
study demonstrated that the type 2 diabetic drug, glibenclamide, was able to reduce 
TXNIP expression levels and IL-1β production in mouse islets142. Glibenclamide also 
known as glyburide is a potassium ATP channel inhibitor that leads to calcium influx and 
insulin release.  As the NLRP3 inflammasome requires potassium efflux for its 
activation, glibenclamide was able to inhibit its activation. Thus glibenclamide and 
development of more specific NLRP3 inhibitors may be beneficial in preventing diabetes 
progression.  
Collectively, potential therapies are beginning to emerge that target ER stress, 
oxidative stress, and inflammation (Figure 3.2). As these different cellular processes are 
connected in the context of type 2 diabetes, targeting components that link these 
pathways will be especially effective in preventing β-cell failure. Approved drugs that 
already demonstrate mechanisms targeting these pathways such as the calcium channel 
blocker verapamil, the GLP-1 analogue exanatide, the PPARγ agonist pioglitazone, the 
IL-1β antagonist anakinra, and the ATP potassium channel blocker glibenclamide could 
potentially be administered to prediabetic patients to prevent type 2 diabetes.  As the 
other compounds discussed must be tested in vivo and in humans, research on more 
selective drugs targeting signaling components of ER stress, oxidative stress and 
inflammation will provide improved therapies for diabetes. 
Moreover it is essential as we do here to decipher the signaling network involved 
in ER stress, oxidative stress, and inflammation to reveal novel drug targets.  TXNIP 
seems to link these different processes and therefore is an attractive molecule to  
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Figure 3.2 Targeting components of TXNIP signaling network for diabetes intervention. (A) 
Progress is being made on deciphering the signaling pathways involved in TXNIP induction and 
function in β-cells. The components involved are potential therapeutic targets to prevent or delay 
the onset of diabetes. (B) Several drugs are being recognized for their ability to target different 
components of TXNIP signaling network and demonstrate promise in preventing type 2 diabetes. 
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investigate. We have found that TXNIP mediates ER stressed induced β-cell death and 
inflammation. But several unanswered questions remain (Figure 3.3). Further studies 
should elucidate how TXNIP mediates β-cell death, does TXNIP bind and inhibit 
thioredoxin, does this result to activation of apoptotic pathways and/or production of 
ROS, and where do TXNIP and the NLRP3 inflammasome localize and how does this 
localization change under ER stress in β-cells. These future studies in addition to others 
will pave the road to delay or even prevent type 2 diabetes. 
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Figure 3.3 Future TXNIP studies under ER stress. Regardless of the progress being made on 
understanding the mechanisms involved in TXNIP induction and function several remaining 
questions require investigation. 
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